CN107098871A - Phenylpropionyl amine derivant, its preparation method and its in application pharmaceutically - Google Patents
Phenylpropionyl amine derivant, its preparation method and its in application pharmaceutically Download PDFInfo
- Publication number
- CN107098871A CN107098871A CN201710095021.XA CN201710095021A CN107098871A CN 107098871 A CN107098871 A CN 107098871A CN 201710095021 A CN201710095021 A CN 201710095021A CN 107098871 A CN107098871 A CN 107098871A
- Authority
- CN
- China
- Prior art keywords
- amino
- alkyl
- heterocyclic radical
- compound
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CC(C)C[C@](C(NC(CCCCN)C(N(CC1)CCC1NC(NC)=O)=*)=O)NC(C(Cc1ccccc1)NC(C(Cc1ccccc1)N)=O)=* Chemical compound CC(C)C[C@](C(NC(CCCCN)C(N(CC1)CCC1NC(NC)=O)=*)=O)NC(C(Cc1ccccc1)NC(C(Cc1ccccc1)N)=O)=* 0.000 description 23
- ZWNYGGDMCSIJNS-UHFFFAOYSA-N CCNC(NC1CCNCC1)=O Chemical compound CCNC(NC1CCNCC1)=O ZWNYGGDMCSIJNS-UHFFFAOYSA-N 0.000 description 2
- WTFBCXIXTUSYKL-UHFFFAOYSA-N C(C1)CN2C1COCC2 Chemical compound C(C1)CN2C1COCC2 WTFBCXIXTUSYKL-UHFFFAOYSA-N 0.000 description 1
- WPNBKGJUKUBUEH-RGURZIINSA-N C=C=[N]1(CC(CCC2)[C@@H]2C1)=C Chemical compound C=C=[N]1(CC(CCC2)[C@@H]2C1)=C WPNBKGJUKUBUEH-RGURZIINSA-N 0.000 description 1
- LRLNTIBVCNNBGL-UHFFFAOYSA-N C=NC(NC1CC(C2)C2NCC1)=O Chemical compound C=NC(NC1CC(C2)C2NCC1)=O LRLNTIBVCNNBGL-UHFFFAOYSA-N 0.000 description 1
- BRTOCHUSJOEHBZ-GHVWMZMZSA-N CC(C)(C)OC(NCCCC[C@H](C(O)=[U])NC(CCCC(c1c-2cccc1)c1c-2cccc1)=O)=[U] Chemical compound CC(C)(C)OC(NCCCC[C@H](C(O)=[U])NC(CCCC(c1c-2cccc1)c1c-2cccc1)=O)=[U] BRTOCHUSJOEHBZ-GHVWMZMZSA-N 0.000 description 1
- FOECYGNKRZBEDD-UHFFFAOYSA-N CC(C)(C=C1)C=CC(O2)=C1NC2=O Chemical compound CC(C)(C=C1)C=CC(O2)=C1NC2=O FOECYGNKRZBEDD-UHFFFAOYSA-N 0.000 description 1
- FVDRGBSQLUTTAA-UHFFFAOYSA-N CC(C)(C=C1)C=Cc2c1[nH]cn2 Chemical compound CC(C)(C=C1)C=Cc2c1[nH]cn2 FVDRGBSQLUTTAA-UHFFFAOYSA-N 0.000 description 1
- RBSYDYCNDOXABE-UHFFFAOYSA-N CC(C)(C=C1)C=Cc2c1nc[s]2 Chemical compound CC(C)(C=C1)C=Cc2c1nc[s]2 RBSYDYCNDOXABE-UHFFFAOYSA-N 0.000 description 1
- JYETYTQJRZSPOK-UHFFFAOYSA-N CC(CC(C)(C)C=C1)C2=C1[O-]CN2 Chemical compound CC(CC(C)(C)C=C1)C2=C1[O-]CN2 JYETYTQJRZSPOK-UHFFFAOYSA-N 0.000 description 1
- LHBBCAVGVCFZSP-UHFFFAOYSA-N CC(NC)N1CC=C(CC2)C2C1 Chemical compound CC(NC)N1CC=C(CC2)C2C1 LHBBCAVGVCFZSP-UHFFFAOYSA-N 0.000 description 1
- CAXQEPUTRSXRFF-UHFFFAOYSA-N CC1(C)C=Cc([nH]nc2)c2C=C1 Chemical compound CC1(C)C=Cc([nH]nc2)c2C=C1 CAXQEPUTRSXRFF-UHFFFAOYSA-N 0.000 description 1
- VXCMFPWVADIDAL-UHFFFAOYSA-N CC1(C)C=Cc([o]cc2)c2C=C1 Chemical compound CC1(C)C=Cc([o]cc2)c2C=C1 VXCMFPWVADIDAL-UHFFFAOYSA-N 0.000 description 1
- IYYOPQOMKXLYFI-CLTKARDFSA-N CCC(/C(/C=C1)=C\C)OC1=O Chemical compound CCC(/C(/C=C1)=C\C)OC1=O IYYOPQOMKXLYFI-CLTKARDFSA-N 0.000 description 1
- PBARHCTYMDDEAQ-BTQNPOSSSA-N CNC(CNCCCC[C@H](C(N(CC1)CCC1NC(NC)=O)=[U])N)=O Chemical compound CNC(CNCCCC[C@H](C(N(CC1)CCC1NC(NC)=O)=[U])N)=O PBARHCTYMDDEAQ-BTQNPOSSSA-N 0.000 description 1
- QZVQYNVEZLUFGU-UHFFFAOYSA-N CNC1C=C2OCC2C1 Chemical compound CNC1C=C2OCC2C1 QZVQYNVEZLUFGU-UHFFFAOYSA-N 0.000 description 1
- GCIWAIUMHMMOID-UHFFFAOYSA-N CNCCCCC(C(N(CC1)CCC1NC(NC)=O)=O)NC(OCc1ccccc1)=O Chemical compound CNCCCCC(C(N(CC1)CCC1NC(NC)=O)=O)NC(OCc1ccccc1)=O GCIWAIUMHMMOID-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to phenylpropionyl amine derivant, its preparation method and its in application pharmaceutically.Especially, pharmaceutical composition the present invention relates to the phenylpropionyl amine derivant shown in logical formula (I), its preparation method and containing the derivative, and it is as the purposes of kappa opioid nonopioid receptors (KOR acceptors) activator, and its purposes in the medicine for the treatment of and/or pre- pain and pain related disorders is prepared.Each substituent of its formula of (I) is identical with the definition in specification.
Description
Technical field
The invention belongs to field of medicaments, it is related to a kind of phenylpropionyl amine derivant, its preparation method and its pharmaceutically
Application.Especially, spread out the present invention relates to the phenylpropionyl amine derivant shown in logical formula (I), its preparation method and containing this
Biological pharmaceutical composition, and its as the purposes of kappa opioid nonopioid receptors (KOR acceptors) activator and its treat preparing
And/or the purposes in the medicine of pre- pain and pain related disorders.
Background technology
Opiate receptor is the important g protein coupled receptor of a class, is the target that endogenous opiatepeptide and opioid drug are combined
Point, immune to nervous system after opiate receptor activation and internal system has adjustment effect, and opioid drug is most strong at present
And conventional central analgesia medicine.Endogenous opiatepeptide is the opioid activity material naturally occurred in mammal body, at present
The endogenous opiatepeptide known is roughly divided into enkephalins, endorphin, dynorphin and several classes of new deltorphin delta (Pharmacol Rev 2007;
59:88-123), there is its corresponding opiate receptor, i.e. μ, δ, kappa receptor etc. in central nervous system.
Kappa opioid receptor (κ-opioid receptor, KOR) is made up of 380 amino acid, and dynorphin is that its endogenous is matched somebody with somebody
Body.There is expression in sensory neuron, Dorsal Root Ganglion Neurons and primary afferent neuron tip, participate in the pain sensation, nerve interior
The important physiological activities such as secretion, affective behavior and cognition.People KOR is currently known by OPRK1 gene codes, chromosome is positioned at
8q11-12 sites (Simonin F, Gaveriaux Ruff C, Kieffer BL, et al.Proc Natl Acad Sci
USA 1995,92(15):7006-10).KOR is activated and G-protein Gi/G0Coupling, adds phosphodiesterase activity, suppresses gland sweet
The activity of cyclase of acid, reduces intracellular cAMP levels, so as to produce the inhibitory action to neuron.KOR activator repeated actions
Acceptor has desensitization effect, and the inhibitory action to gland sweet acid cyclase activity reduces (Raynor K, Kong H, Hines J, et
al.J Pharmacol Exp Ther,1994,270:1381-6).KOR is also logical with inward rectifyimg potassium channel and N-type calcium ion
Road is coupled (Henry DJ, Grandy DK, Lester HA, Davidson N, Chavkin C (Mar 1995) Molecular
Pharmacology 47(3):551–7).KOR activators can suppress the injury of (calcium ion dependence) peripheral sensory nerve endings
The release of Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2 before preceding and inflammation, this is probably the reason for it has anti-nociceptive effects and antiinflammatory action.Except dynorphin, respectively
Planting the part of natural alkaloid and synthesis can also be combined with KOR.KOR provide natural habituation controlling mechanism, therefore, as by
The medicine of body activator has the potentiality of drug-addiction treatment.
Effect of the KOR activators Asimadoline (asimadoline) in rodent diabetes DPN
(Jolivalt et al.Diabetologia 2006,49(11):2775-85;Epub Aug.19) and KOR activators U-
50488 effect and opioid antagonists in repressive damage (CCI) model of rat chronic of neuropathic pain receives Lip river
Blocking (Bileviciute-Ljungar et al.Eur.J.Pharm 2004.494 of the ketone (naloxone) to its effect:
139-46), these observation results are supported to be used to KOR activators treat the neuropathic pain that diabetes, virus and chemotherapy trigger.
KOR activators are used to treat or prevent including such as the splanchnodynia including the gynecological diseases such as dysmenorrhoea spasm and endometriosis
Using also be evaluated (Riviere, Br.J.Pharmacol 2004.141:1331-4).
Kappa opioid material activator increase water renal excretion and reduce natruresis (i.e. produce optional water diuresis, also by
Referred to as promote water excretion), many researchers think that this effect is due to suppress pituitary antidiuretic hormone.Compare maincenter work
With property and it is said that the research institute of the selective kappa opioid material of periphery property is concluded that KOR in blood-brain barrier is responsible for
Mediate this effect.There is researcher to propose to act on the plain peptide of nociception or powered peptide of the plain acceptor of nociception in periphery
Conjugate treats hyponatremia, described injury experience peptide acceptor and KOR about but it is different (D.R.Kapusta, Life Sci.,
60:15-21,1997)。
Presently disclosed KOR activators patent application include WO20071398, WO2008060552, WO09932510,
WO2013184794, WO2014089019, WO2014184356 and WO2015065867.
Kappa opioid nonopioid receptors (KOR acceptors) activator has a good application prospect as medicine in pharmaceuticals industry, is
The purpose of more preferable therapeutic effect is reached, the market demand is better met, inventor wishes to develop the efficient of a new generation
The KOR activators of low toxicity.The present invention will provide a kind of new kappa opioid nonopioid receptors (KOR acceptors) agonist compound, suchization
Compound astoundingly shows excellent effect and effect.
The content of the invention
It is an object of the invention to provide the compound shown in a kind of logical formula (I):
Or its dynamic isomer, mesomer, racemic modification, enantiomter, diastereoisomer or its mixture shape
Formula, or its pharmaceutically useful salt,
Wherein:
G is C=O or O=S=O;
R1Selected from hydrogen atom, alkyl, alkoxy, haloalkyl, halogen, amino, nitro, hydroxyl, cyano group, cycloalkyl, miscellaneous
Ring group, aryl, heteroaryl ,-OR3、-C(O)R3、-C(O)OR3、-S(O)mR3With-NR4R5, wherein described alkyl, alkyl halide
Base, cycloalkyl, heterocyclic radical, aryl and heteroaryl are optionally selected from alkyl, haloalkyl, halogen, amino, nitro, cyano group, hydroxyl
Base, alkoxy, halogenated alkoxy, hydroxyalkyl, cycloalkyl, heterocyclic radical, aryl, heteroaryl and NR6R7One or more of substitution
Base is replaced;
R2Selected from hydrogen atom, alkyl, alkoxy, haloalkyl, cycloalkyl, heterocyclic radical, aryl, heteroaryl ,-OR3、-C(O)
R3With-C (O) OR3, wherein described alkyl, haloalkyl, cycloalkyl, heterocyclic radical, aryl and heteroaryl be optionally selected from alkyl,
Haloalkyl, halogen, amino, nitro, cyano group, hydroxyl, alkoxy, halogenated alkoxy, hydroxyalkyl, cycloalkyl, heterocyclic radical, aryl
Replaced with one or more of heteroaryl substituent;
R3Selected from hydrogen atom, alkyl, amino, alkoxy, hydroxyalkyl, cycloalkyl, heterocyclic radical, aryl and heteroaryl, wherein
Described alkyl, cycloalkyl, heterocyclic radical, aryl and heteroaryl be optionally selected from alkyl, halogen, hydroxyl, amino, nitro, cyano group,
One or more of alkoxy, hydroxyalkyl, cycloalkyl, heterocyclic radical, aryl and heteroaryl substituent is replaced;
R4And R5It is each independently selected from hydrogen atom, alkyl, alkoxy, hydroxyalkyl, hydroxyl, amino, carboxylic acid ester groups, cycloalkanes
Base, heterocyclic radical, aryl and heteroaryl, wherein described alkyl, cycloalkyl, heterocyclic radical, aryl and heteroaryl are optionally selected from alkane
Base, halogen, hydroxyl, amino, carboxylic acid ester groups, nitro, cyano group, alkoxy, hydroxyalkyl, cycloalkyl, heterocyclic radical, aryl and heteroaryl
One or more of substituent replaced;
R6For hydrogen atom or W;
R7Selected from hydrogen atom, alkyl, C (O) R8、C(O)OR8、C(O)NR9R10Or W, wherein described alkyl is optionally selected from
One or more of alkoxy, hydroxyalkyl, cycloalkyl, heterocyclic radical, carboxylic acid group and carboxylic acid ester groups substituent is replaced;
R8Selected from hydrogen atom, alkyl, alkoxy, amino, cycloalkyl and heterocyclic radical, wherein described heterocyclic radical is optionally chosen
Taken from one or more of alkyl, alkoxy, hydroxyalkyl, cycloalkyl, heterocyclic radical, carboxylic acid group and carboxylic acid ester groups substituent
Generation;
R9And R10It is each independently selected from hydrogen atom, alkyl or haloalkyl;Wherein described alkyl is optionally selected from carboxylic
One or many in acidic group, alkoxy, amino, cyano group, nitro, hydroxyl, hydroxyalkyl, cycloalkyl, heterocyclic radical, aryl and heteroaryl
Individual substituent is replaced;
Or, R9And R10Heterocyclic radical is formed together with the nitrogen-atoms being connected, wherein containing 1~2 in described heterocyclic radical
The individual identical or different hetero atom selected from N, O and S, and described heterocyclic radical is optionally selected from alkyl, alkoxy, halogen, ammonia
One in base, cyano group, nitro, hydroxyl, hydroxyalkyl, cycloalkyl, heterocyclic radical, carboxylic acid group, carboxylic acid ester groups, aryl and heteroaryl or
Multiple substituents are replaced;
W is amino protecting group;And
M is 0,1 or 2.
In yet other embodiments, the compound shown in described logical formula (I) is shown in logical formula (II)
Compound:
Or its dynamic isomer, mesomer, racemic modification, enantiomter, diastereoisomer or its mixture shape
Formula, or its officinal salt,
Wherein:
R1And R2As defined in logical formula (I).
In yet other embodiments, the compound shown in described logical formula (I), wherein R1For alkyl or
OR3, wherein described alkyl is optionally by NR6R7Substituent is replaced;
R3Selected from alkyl or heterocyclic radical, wherein described alkyl is optionally selected from cycloalkyl, heterocyclic radical, aryl and heteroaryl
One or more of substituent replaced;
R6For hydrogen atom;
R7Selected from hydrogen atom, alkyl, C (O) OR8Or C (O) NR9R10, wherein described alkyl is optionally selected from alkoxy, hydroxyl
One or more of alkyl, carboxylic acid group and carboxylic acid ester groups substituent is replaced;
R8For hydrogen atom or alkyl;
R9And R10It is each independently hydrogen atom or alkyl;
Or, R9And R10Heterocyclic radical is formed together with the nitrogen-atoms being connected, wherein containing 1~2 in described heterocyclic radical
The individual identical or different hetero atom selected from N, O and S, and described heterocyclic radical is optionally selected from alkyl, alkoxy, halogen, ammonia
One or more of base, carboxylic acid group and carboxylic acid ester groups substituent is replaced.
In yet other embodiments, the compound shown in described logical formula (I) is shown in logical formula (III)
Compound:
Or its dynamic isomer, mesomer, racemic modification, enantiomter, diastereoisomer or its mixture shape
Formula, or its officinal salt,
Wherein:
G、R6~R7And R2As defined in logical formula (I).
In yet other embodiments, the compound shown in described logical formula (I)~logical formula (III), its
Middle R2Selected from hydrogen atom, alkyl, cycloalkyl and aryl;Preferably hydrogen atom, methyl, ethyl, cyclopropyl or phenyl.
The typical compound of logical formula (I), includes but is not limited to:
Or its dynamic isomer, mesomer, racemic modification, enantiomter, diastereoisomer or its mixture shape
Formula, or its officinal salt.
The present invention additionally provides a kind of logical formula (I) compound or its salt, wherein described salt is logical formula (I) and trifluoroacetic acid
The addition salts of formation.
The present invention additionally provides the compound shown in a kind of logical formula (IV), the intermediate for synthesizing logical formula (I):
Or its dynamic isomer, mesomer, racemic modification, enantiomter, diastereoisomer or its mixture shape
Formula or its pharmaceutically useful salt,
Wherein:
W is amino protecting group;
G and R1~R2As defined in logical formula (I).
The typical compound of logical formula (IV), includes but is not limited to:
Or its dynamic isomer, mesomer, racemic modification, enantiomter, diastereoisomer or its mixture shape
Formula, or its officinal salt.
Prepared the present invention additionally provides one kind according to logical formula (I) compound or its dynamic isomer, mesomer, racemic
Body, enantiomter, diastereoisomer or its form of mixtures or the method for its officinal salt, this method include:
Formula (I-5) compound is reacted with formula (I-6) compound, obtains logical formula (IV) compound;Obtained formula
(IV) compound further sloughs protection group, obtains logical formula (I) compound;
Wherein:
W is amino protecting group;
G、R1And R2As defined in logical formula (I).
Another aspect of the present invention is related to a kind of pharmaceutical composition, its contain treatment effective dose above-mentioned logical formula (I),
(II) compound, shown in (III) or its dynamic isomer, mesomer, racemic modification, enantiomter, diastereo-isomerism
Body or its form of mixtures or pharmaceutically useful salt, and one or more pharmaceutically acceptable carriers, diluent or figuration
Agent.The invention further relates to a kind of method for preparing aforementioned pharmaceutical compositions, it is included shown in logical formula (I), (II), (III)
Compound or its dynamic isomer, mesomer, racemic modification, enantiomter, diastereoisomer or its mixture shape
Formula or its pharmaceutically useful salt are mixed with pharmaceutically acceptable carrier, diluent or excipient.
In one embodiment, pharmaceutical composition of the invention further comprises one or more kinds of following compounds:
Opioid, cannboid, antidepressant, anticonvulsant, tranquilizer, corticosteroid, ion channel blocking agent or non-steroidal are anti-
Scorching medicine (NSAID).
The invention further relates to the compound shown in logical formula (I), (II), (III) or its dynamic isomer, meso
Body, racemic modification, enantiomter, diastereoisomer or its form of mixtures or its officinal salt, or the medicine comprising it
Composition purposes in the medicine of excitement or antagonism kappa opioid nonopioid receptors (KOR acceptors) is prepared.
The invention further relates to the compound shown in logical formula (I), (II), (III) or its dynamic isomer, meso
Body, racemic modification, enantiomter, diastereoisomer or its form of mixtures or its officinal salt, or the medicine comprising it
Composition is in the medicine for preparing the relevant disease for preventing and/or treating the mediation of kappa opioid nonopioid receptors (KOR acceptors) activator
Purposes in thing, the relevant disease of kappa opioid nonopioid receptors (KOR acceptors) receptor stimulating agent mediation be preferably selected from pain,
Inflammation, itch, oedema, hyponatremia, hypopotassaemia, intestinal obstruction, cough and glaucoma, more preferably pain.
The invention further relates to the compound shown in logical formula (I), (II), (III) or its dynamic isomer, meso
Body, racemic modification, enantiomter, diastereoisomer or its form of mixtures or its officinal salt, or the medicine comprising it
Composition is being prepared for preventing and/or treating mammal (for example:People) pain and pain related disorders medicine in use
On the way, wherein described pain can be postoperative pain, pain, neuropathic pain, treatment of traumatic pain and inflammation caused by cancer draw
Pain risen etc..
The invention further relates to a kind of excitement or the method for antagonism kappa opioid nonopioid receptors (KOR acceptors), this method bag
Include to need the logical formula (I) of the invention of its patient therapeuticallv's effective dose, (II), the compound shown in (III) or its
Dynamic isomer, mesomer, racemic modification, enantiomter, diastereoisomer or its form of mixtures or its is pharmaceutically acceptable
Salt.
, should the invention further relates to a kind of method for the relevant disease for preventing and/or treating the mediation of KOR agonist receptors
Method includes the chemical combination shown in the logical formula (I) of the invention of its patient therapeuticallv's effective dose of needs, (II), (III)
Thing or its dynamic isomer, mesomer, racemic modification, enantiomter, diastereoisomer or its form of mixtures or its
Officinal salt.This method shows prominent curative effect and less side effect.Wherein described kappa opioid nonopioid receptors (KOR by
Body) agonist receptor mediation relevant disease be selected from pain, inflammation, itch, oedema, hyponatremia, hypopotassaemia, intestinal obstruction,
Cough and glaucoma, preferably pain.
The invention further relates to the compound shown in a kind of logical formula (I) as medicine, (II), (III) or its change
Isomers, mesomer, racemic modification, enantiomter, diastereoisomer or its form of mixtures or its officinal salt.
The invention further relates to the compound shown in logical formula (I), (II), (III) or its dynamic isomer, meso
Body, racemic modification, enantiomter, diastereoisomer or its form of mixtures or its officinal salt, it is used for exciting or short of money
Anti- kappa opioid nonopioid receptors (KOR acceptors).
The invention further relates to the compound shown in logical formula (I), (II), (III) or its dynamic isomer, meso
Body, racemic modification, enantiomter, diastereoisomer or its form of mixtures or its officinal salt, its be used for prevent and/
Or the relevant disease for the treatment of KOR receptor stimulating agent mediations.
The invention further relates to the compound shown in logical formula (I), (II), (III) or its dynamic isomer, meso
Body, racemic modification, enantiomter, diastereoisomer or its form of mixtures or its officinal salt, its be used for prevent and/
Or treatment mammal is (for example:People) pain and pain related disorders.Kappa opioid nonopioid receptors (KOR acceptors) activator
The relevant disease of mediation, the disorderly or patient's condition can be the correlations of any kappa opioid nonopioid receptors (KOR acceptors) activator mediation
The patient's condition, including but not limited to acute or chronic pain, inflammation, itch, hyponatremia, oedema, intestinal obstruction, cough and green light
Eye.For example, the related pain of kappa opioid nonopioid receptors (KOR acceptors) can be neuropathic pain, somatalgia, splanchnodynia or skin
Skin pain.Some diseases, disorder or the patient's condition are relevant with more than one pain form.For example, postoperative pain can be nerve pain
Bitterly, any of somatalgia, splanchnodynia or dermatalgia factor or all, this depend on used surgical operation type and
Degree.
The related inflammation of kappa opioid nonopioid receptors (KOR acceptors) of the present invention can be any inflammatory disease or disease
Condition, including but not limited to sinusitis, rheumatoid arthritis tenosynovitis, bursal synovitis, tendonitis, external humeral epicondylitis, sticky capsulitis, bone
Marrow inflammation, osteoarthritic inflammation, inflammatory bowel disease (IBD), IBS (IBS), inflammation of eye section, ear inflammation or autoimmunity are scorching
Disease.
The related itch of kappa opioid nonopioid receptors (KOR acceptors) of the present invention can be any pruritic condition and disease
The related ocular pruritis of condition, such as ocular pruritis such as conjunctivitis, itch, itch (many of which patient relevant with latter stage nephropathy
Receive Rend dialysis) and other forms cholestasis, it is including Primary biliary cirrhosis, intrahepatic cholestasis of pregnancy, chronic
Cholesterol hepatopathy, uremia, pernicious cholestasis, jaundice and skin conditions, such as eczema (dermatitis) include atopic dermatitis
Or contact dermatitis, skin tinea, polycythemia, lichen planus, lichen simplex chronicus, pediculosis, thyrotoxicosis, tinea pedis,
Nettle rash, scabies, vaginitis, hemorrhoid related pruritus ani and insect bite itch and drug-induced itch, such as mu opioid
Itch caused by material.
The related oedema of kappa opioid nonopioid receptors (KOR acceptors) of the present invention can be any edema disease or
Oedema caused by the patient's condition, such as congestive heart disease or antidiuretic hormone (ADH) secrete oedema caused by improper syndrome.
The related intestinal obstruction of kappa opioid nonopioid receptors (KOR acceptors) of the present invention can be any intestinal obstruction disease
Or the patient's condition, bowel dysfunction including but not limited to caused by post operative ileus or opioid.
The related neuropathic pain of kappa opioid nonopioid receptors (KOR acceptors) of the present invention can be any nerve
Pain, for example, the related pain of pain such as herpes zoster, chemotherapy trigger caused by trigeminal neuralgia, diabetic pain, virus
Pain, the metastatic cancer pain of invasion and attack nerve, the wound neuropathic pain related to surgical operation and various be considered as having
There is the headache variant such as migraines of europathology factor.
The related pain of kappa opioid nonopioid receptors (KOR acceptors) of the present invention is coughed including ocular pain, for example, bending
Eye pain after photosensitiveness cornea ablation art (PRK), eye tear, eyeground fracture, chemical burn, abrasio corneae or stimulation etc.
Bitterly, or with conjunctivitis, ulcer of the cornea, sclerotitis, episcleritis, sclerokerratitis, herpes zoster ophthalmicus, chromic fibrous cornea
Inflammation, acute iritis, keratoconjunctivitis sicca, orbital cell ulitis, orbital pseudotumor, pemphigus, trachoma or uveitis are related
Ocular pain.
The related pain of kappa opioid nonopioid receptors (KOR acceptors) of the present invention is also wrapped work and had a sore throat, especially with inflammation
Symptom condition, such as allergic rhinitis, acute bronchitis, common cold, contact ulcer, herpes simplex virus damage, infection
Property monocytosis,mononucleosis, influenza, laryngocarcinoma, acute laryngitis, acute necrotizing ulcer gingivitis, tonsil abscess, pharynx
Portion is burnt, pharyngitis, reflux sphagitis, acute sinusitis is related to tonsillitis has a sore throat.
The related pain of kappa opioid nonopioid receptors (KOR acceptors) of the present invention can be arthritis ache, kidney knot
Stone, lithangiuria and calculus of bile duct pain, hysterotrismus, dysmenorrhoea, endometriosis, mastitis, indigestion, surgery hand
Postoperative pain (for example appendectomy, open colorectal resection, hernia reparation, prostatectomy, colon enucleation,
Gastrectomy, splenectomy, colectomy, colostomy, pelvis abdominoscopy book, tubal ligation, uterectomy,
Postoperative pain caused by vasectoray or cholecystectomy), pain (such as colonoscopy, bladder after medical treatment
Pain after spectroscopy, hysteroscopy or uterine neck or endometrial biopsy), otitis pain, explosive cancer
Pain and the pain related to GI disorders, GI the disorder such as IBD or IBS or other inflammatory conditions, especially encelitis
Disease is (for example, GORD, pancreatitis, acute pyelonephritis, ulcerative colitis, cholecystitis, hepatic sclerosis, hepatic pouch
Swollen, hepatitis, duodenal ulcer or gastric ulcer, esophagitis, gastritis, gastroenteritis, colitis, diverticulitis, intestinal obstruction, ovarian bursa
Swollen, pelvic inflammatory disease, perforated ulcer, peritonitis, prostatitis, interstitial cystitis) related pain, or connect with toxic agent
Touch the pain that (medicine such as insect toxins or such as salicylate (salt) or NSAID) is brought.
The related hyponatremia of kappa opioid nonopioid receptors (KOR acceptors) of the present invention can the presence of hyponatremia
Any disease or the patient's condition of (the low sodium patient's condition),, extremely can be with when na concn is less than 135mmol/l in blood plasma for example, in people
Individually occur, or more insights are as the complication of other medical conditions or as using can cause the medicine of sodium deficiency
As a result occur, wherein the disease related to hyponatremia includes but is not limited to:Cause the tumour of excessive ADH secretion because
Element, including lung, duodenum, pancreas, ovary, cancer, thymoma, celiothelioma, bronchial adenoma, the class cancer of bladder and ureter
Knurl, gangliocytoma and Ewing's sarcoma, infection;Such as pneumonia (bacillary or viral), abscess (lung or brain), sky
Bubble forms (aspergillosis), tuberculosis (lung or brain), meningitis (bacillary or viral), encephalitis and AIDS;Vascular factor example
Such as:Cerebral infarction or hemorrhage and cavernous sinus thrombosis;Neural factors are for example:Guillan-Barre syndromes, multiple sclerosis,
Delirium tremens, ALS, hydrocephalus, mental disease, peripheral neurophaty, head trauma (closed and penetrability),
Cns tumor or infection and the CNS infringements for influenceing hypothalamus osmoreceptor;Congenital abnormality bag is lived:Corpus callosum is developed not
Entirely, harelip and line defect in other;Metabolic factor is for example:Acute intermittent porphyria, asthma, pneumothorax and positive pressure respiration;Medicine
Thing is for example:Thiazide diuretic, paracetamol, barbiturate, cholinergic agent, estrogen, oral hypoglycemic, pitressin are gone
Ammonia pitressin, high dose oxytocins chlorpropamide, vincristine, carbamazepine, nicotine, phenthazine, endoxan, three rings resist
Down, MAOI and serotonin reuptake inhibitor;For example during hospitalization, surgical operation or physical culture
(that is, related hyponatremia, which is moved, during or after activity) applies excessive hypotonic fluid, and using low in older individuals
Sodium nutrition replenishers, other patient's condition related to hyponatremia include renal failure, nephrotic syndrome (model nephrosis and minute lesion disease
Disease), pernicious matter, malnutrition, rhabdomyolysis, surgery processing, selective cardiac catheterization, lose blood and hypercalcinemia, low
Potassium mass formed by blood stasis and result are the hyperglycemias for the glycosuria that can cause osmotic diuresis.
Another aspect of the present invention is related to a kind of be used as and prevented and/or treatment kappa opioid nonopioid receptors (KOR acceptors) activator
The method of the relevant disease of mediation, disorderly or patient's condition relevant disease, this method, which includes its patient therapeuticallv to needs, to be had
Each formula of the invention of dosage is imitated, particularly leads to compound or its dynamic isomer, mesomer shown in formula (I), disappear outside
Revolve body, enantiomter, diastereoisomer or its form of mixtures or its officinal salt;This method shows the treatment of protrusion
Effect and less side effect, wherein the relevant disease of described kappa opioid nonopioid receptors (KOR acceptors) activator mediation include but
It is not limited to acute or chronic pain, inflammation, itch, hyponatremia, oedema, intestinal obstruction, cough and glaucoma.
Another aspect of the present invention is related to a kind of method prevented and/or treat mammalian pain and pain related disorders,
This method is included to its mammal of needs using shown in the logical formula (I) of the invention for the treatment of effective dose, (II), (III)
Compound or its dynamic isomer, mesomer, racemic modification, enantiomter, diastereoisomer or its mixture shape
Formula or its officinal salt;This method shows prominent curative effect and less side effect, wherein described pain can be postoperative
Ache caused by pain, neuropathic pain, treatment of traumatic pain somatalgia, splanchnodynia, dermatalgia and inflammation caused by pain, cancer
Bitterly, for example, postoperative pain can be any of neuropathic pain, somatalgia, splanchnodynia or dermatalgia factor or whole, this
Depending on the type and extent of the surgical operation used;Described cancer can be selected from breast cancer, carcinoma of endometrium, uterine neck
Cancer, cutaneum carcinoma, prostate cancer, oophoroma, fallopian tube cneoplasms, ovarioncus, hemophilia and leukaemia etc..
Pharmaceutical composition containing active component can apply to oral form, such as tablet, dragee, lozenge, water
Or oil suspension, dispersible powder or particle, emulsion, hard or soft capsule, or syrup or elixir.Can be any according to this area
Know that the method for preparing Pharmaceutical composition prepares Orally administered composition, such composition can containing it is one or more selected from it is following into
Point:Sweetener, flavouring, colouring agent and preservative, to provide pleasing and tasty pharmaceutical formulation.Tablet contain active component and
The suitable nontoxic pharmaceutically useful excipient for preparing tablet for mixing.These excipient can be inert excipient, such as carbon
Sour calcium, sodium carbonate, lactose, calcium phosphate or sodium phosphate;Granulating agent and disintegrant, such as microcrystalline cellulose, cross-linked carboxymethyl fiber
Plain sodium, cornstarch or alginic acid;Adhesive, such as starch, gelatin, polyvinylpyrrolidone or Arabic gum;And lubricant, example
Such as magnesium stearate, stearic acid or talcum powder.These tablets can not be coated or can be by covering the taste of medicine or in intestines and stomach
Middle delay disintegration and absorption, thus the known technology of offer slow releasing function is coated in a long time.For example, water can be used
Dissolubility taste masked material, such as hydroxypropyl methyl cellulose or hydroxypropyl cellulose, or extension time material such as ethyl are fine
Dimension element, acetylbutyrylcellulose.
What also available wherein active component was mixed with inert solid diluent such as calcium carbonate, calcium phosphate or kaolin is hard bright
Glue capsule, or wherein active component and water-solubility carrier such as polyethylene glycol or oily solvent such as peanut oil, atoleine or olive
The Perle of olive oil mixing provides oral formulations.
Water slurry contains active material and the suitable excipient for preparing water slurry for mixing.Such excipient is
Suspending agent, such as sodium carboxy methyl cellulose, methylcellulose, hydroxypropyl methyl cellulose, mosanom, polyvinylpyrrolidone
And Arabic gum;Dispersant or wetting agent can be naturally-produced phosphatide such as lecithin, or alkylene oxide and aliphatic acid contracting
Close product such as Myrj 45, or oxirane and long-chain fatty alcohol condensation product, such as 17 carbon ethylidene
Epoxide cetanol, or oxirane with as derived from aliphatic acid and hexitol part ester condensation product, such as PEO
Sorbitol monooleate, or oxirane with as derived from aliphatic acid and hexitan partial ester condensation product, such as polycyclic oxygen
Ethane Arlacel-80.Aqueous suspension can also contain one or more preservative such as ethylparabens or Ni Bo
Nintaus's propyl ester, one or more colouring agent, one or more flavourings and one or more sweeteners, such as sucrose, saccharin or
Aspartame.
Oil suspension can by making active component be suspended in vegetable oil such as peanut oil, olive oil, sesame oil or coconut oil, or
It is formulated in mineral oil such as atoleine.Oil suspension can contain thickener, such as beeswax, hard paraffin or cetanol.Can
Above-mentioned sweetener and flavouring is added, to provide tasty preparation.Can by add antioxidant such as Butylated Hydroxyanisole or α-
These compositions of fertility phenol preservation.
The dispersible powder and particle being suspended also by adding water to make suitable for preparing water provide active component and are used for
The dispersant or wetting agent of mixing, suspending agent or one or more preservatives.Suitable dispersant or wetting agent and suspending agent can
Illustrate above-mentioned example.Also other excipient such as sweetener, flavouring and colouring agent can be added.By adding antioxidant example
As ascorbic acid preserves these compositions.
The pharmaceutical composition of the present invention can also be the form of oil in water emulsion.Oil phase can be vegetable oil such as olive oil
Or peanut oil, or mineral oil such as atoleine or its mixture.Suitable emulsifying agent can be naturally-produced phosphatide, for example
Soybean lecithin and ester or partial ester such as sorbitan monooleate as derived from aliphatic acid and hexitan, and the partial ester and ring
The condensation product of oxidative ethane, such as polyoxyethylene sorbitol monoleate.Emulsion can also contain sweetener, flavouring, prevent
Rotten agent and antioxidant.Syrup and elixir can be prepared with Sweetening agents such as glycerine, propane diols, sorbierite or sucrose.Such preparation
Moderator, preservative, colouring agent and antioxidant can be contained.
The pharmaceutical composition of the present invention can be sterile injectable aqueous form.The acceptable solvent or molten that can be used
Agent has water, ringer's solution and isotonic sodium chlorrde solution.Aseptic injection preparation can be that wherein active component is dissolved in the sterile of oil phase
Inject oil-in-water microemulsion.For example active component is dissolved in the mixture of soybean oil and lecithin.Then oil solution is added into water
Micro emulsion is formed with processing in the mixture of glycerine.Parenteral solution or micro emulsion can be injected to the blood flow of patient by local a large amount of injections
In.Or, preferably give solution and micro emulsion in the way of it can keep the compounds of this invention constant circulating concentration.To keep this perseverance
Determine concentration, continuous intravenous delivery device can be used.The example of this device is that Deltec CADD-PLUS.TM.5400 types are quiet
Arteries and veins syringe pump.
The pharmaceutical composition of the present invention can be aseptic injection water or the shape of oil suspension for intramuscular and subcutaneous administration
Formula.By known technology the suspension can be prepared with the suitable dispersant of those described above or wetting agent and suspending agent.Aseptic injection system
Agent can also be the aseptic injectable solution or suspension prepared in the acceptable non-toxic diluent of parenteral or solvent, such as 1,
The solution prepared in 3- butanediols.In addition, it is convenient to be used as solvent or suspension media with sterile fixed oil.For this purpose, can
Use any mediation fixing oil including synthetic glycerine list or diester.In addition, aliphatic acid such as oleic acid can also prepare note
Penetrate agent.
The compounds of this invention can be given by the suppository form for rectally.Can be by by medicine and at normal temperatures
For solid but be liquid in the rectum, thus the suitable nonirritant excipient mixing of medicine can be dissolved and discharged in the rectum
To prepare these pharmaceutical compositions.Such material includes cocoa butter, glycerin gelatine, hydrogenated vegetable oil, the poly- second of various molecular weight
The mixture of the fatty acid ester of glycol and polyethylene glycol.
As it is well known to the skilled in the art, the dosage of medicine depends on many factors, including it is but and non-limiting
In following factor:The activity of particular compound used, the age of patient, the body weight of patient, the health status of patient, the row of patient
Quilt, the diet of patient, administration time, administering mode, speed, the combination of medicine of excretion etc.;In addition, optimal therapeutic modality is such as
The species of the pattern for the treatment of, the consumption per day of general formula compound (I) or pharmaceutically useful salt can be tested according to traditional therapeutic scheme
Card.
Detailed description of the invention
Unless stated to the contrary, the term used in the specification and in the claims has following implications.
Term " alkyl " refers to saturated aliphatic hydrocarbons group, and it is the straight or branched group for including 1 to 20 carbon atom, excellent
Select the alkyl containing 1 to 12 carbon atom, the alkyl of further preferably 1 to 6 carbon atom.Non-limiting examples include methyl,
Ethyl, n-propyl, isopropyl, normal-butyl, isobutyl group, the tert-butyl group, sec-butyl, n-pentyl, 1,1- dimethyl propyls, 1,2- diformazans
Base propyl group, 2,2- dimethyl propyls, 1- ethyl propyls, 2- methyl butyls, 3- methyl butyls, n-hexyl, 1- Ethyl-2-Methyls third
Base, 1,1,2- thmethylpropyls, 1,1- dimethylbutyls, 1,2- dimethylbutyls, 2,2- dimethylbutyls, 1,3- dimethyl butyrates
Base, 2- ethyl-butyls, 2- methyl amyls, 3- methyl amyls, 4- methyl amyls, 2,3- dimethylbutyls, n-heptyl, 2- methyl oneself
Base, 3- methylhexyls, 4- methylhexyls, 5- methylhexyls, 2,3- dimethyl amyl groups, 2,4- dimethyl amyl groups, 2,2- dimethyl
Amyl group, 3,3- dimethyl amyl groups, 2- ethyl pentyl groups, 3- ethyl pentyl groups, n-octyl, 2,3- dimethylhexanyls, 2,4- dimethyl oneself
Base, 2,5- dimethylhexanyls, 2,2- dimethylhexanyls, 3,3- dimethylhexanyls, 4,4- dimethylhexanyls, 2- ethylhexyls, 3-
Ethylhexyl, 4- ethylhexyls, 2- methyl -2- ethyl pentyl groups, 2- methyl -3- ethyl pentyl groups, n-nonyl, 2- methyl -2- ethyls
Hexyl, 2- methyl -3- ethylhexyls, 2,2- diethyl amyl groups, positive decyl, 3,3- diethylhexyls, 2,2- diethylhexyls, and
Its various branched chain isomer etc..Low alkyl group more preferably containing 1 to 6 carbon atom, non-limiting example includes first
Base, ethyl, n-propyl, isopropyl, normal-butyl, isobutyl group, the tert-butyl group, sec-butyl, n-pentyl, 1,1- dimethyl propyls, 1,2-
Dimethyl propyl, 2,2- dimethyl propyls, 1- ethyl propyls, 2- methyl butyls, 3- methyl butyls, n-hexyl, 1- ethyl -2- first
Base propyl group, 1,1,2- thmethylpropyls, 1,1- dimethylbutyls, 1,2- dimethylbutyls, 2,2- dimethylbutyls, 1,3- diformazans
Base butyl, 2- ethyl-butyls, 2- methyl amyls, 3- methyl amyls, 4- methyl amyls, 2,3- dimethylbutyls etc..Alkyl can be with
It is substitution or non-substituted, when substituted, substituent can be substituted on any workable tie point, the substitution
Base is preferably one or more following groups, its independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio group, alkyl amino,
Halogen, sulfydryl, hydroxyl, nitro, cyano group, cycloalkyl, Heterocyclylalkyl, aryl, heteroaryl, cycloalkyloxy, heterocyclylalkoxy groups, cycloalkanes
Sulfenyl, heterocycle alkylthio group, oxo base, carboxyl or carboxylic acid ester groups.
Term " cycloalkyl " refers to saturation or part is unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent, cycloalkyl ring comprising 3 to
20 carbon atoms, preferably comprise 3 to 12 carbon atoms, more preferably comprising 3 to 6 carbon atoms, most preferably comprise 5 to 6 carbon originals
Son.The non-limiting examples of monocyclic cycloalkyl include cyclopropyl, cyclobutyl, cyclopenta, cyclopentenyl, cyclohexyl, cyclohexenyl group,
Cyclohexadienyl, suberyl, cycloheptatriene base, cyclooctyl etc.;Polycyclic naphthene base includes the cycloalkyl of loop coil, condensed ring and bridged ring.
Term " spiro cycloalkyl group " refers to the polycyclic moiety that a carbon atom (title spiro-atom) is shared between 5 to 20 yuan monocyclic,
It can contain one or more double bonds, but neither one ring has the pi-electron system of total conjugated.Preferably 6 to 14 yuan, more
Preferably 7 to 10 yuan.Spiro cycloalkyl group is divided into by single spiro cycloalkyl group, double spirocyclanes according to the number of shared spiro-atom between ring and ring
Base or many spiro cycloalkyl groups, are preferably single spiro cycloalkyl group and double spiro cycloalkyl groups.More preferably 4 yuan/4 yuan, 4 yuan/5 yuan, 4 yuan/6 yuan, 5
Member/5 yuan or 5 yuan/6 yuan single spiro cycloalkyl groups.The non-limiting examples of spiro cycloalkyl group include:
Term " cycloalkyl " refers to each ring in 5 to 20 yuan, system and shared a pair adjoined of other rings in system
The full carbon polycyclic moiety of carbon atom, wherein one or more rings can contain one or more double bonds, but neither one ring has
The pi-electron system of total conjugated.Preferably 6 to 14 yuan, more preferably 7 to 10 yuan.It can be divided into according to the number of composition ring double
Ring, three rings, Fourth Ring or polycyclic fused ring alkyl, preferably bicyclic or three rings, more preferably 5 yuan/5 yuan or 5 yuan/6 membered bicyclic alkyl.
The non-limiting examples of cycloalkyl include:
Term " bridge ring alkyl " refers to 5 to 20 yuan, and the full carbon that any two ring shares two carbon atoms being not directly connected is more
Cyclic group, it can contain one or more double bonds, but neither one ring has the pi-electron system of total conjugated.Preferably 6 to
14 yuan, more preferably 7 to 10 yuan.Bicyclic, three rings, Fourth Ring or polycyclic bridge ring alkyl can be divided into according to the number of composition ring, it is excellent
Elect bicyclic, three rings or Fourth Ring, more preferably bicyclic or three rings as.The non-limiting examples of bridge ring alkyl include:
The cycloalkyl ring can be condensed on aryl, heteroaryl or heterocycloalkyl ring, wherein being connected to precursor structure
Ring together is cycloalkyl, and non-limiting examples include indanyl, tetralyl, benzocyclohepta alkyl etc.;It is preferred that phenyl and ring
Amyl group, tetralyl.Cycloalkyl can be it is optionally substituted or non-substituted, when substituted, substituent be preferably one or
Multiple following groups, it is independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio group, alkyl amino, halogen, sulfydryl, hydroxyl
Base, nitro, cyano group, cycloalkyl, Heterocyclylalkyl, aryl, heteroaryl, cycloalkyloxy, heterocyclylalkoxy groups, cycloalkylthio, heterocycle alkane
Sulfenyl, oxo base, carboxyl or carboxylic acid ester groups.
Term " heterocyclic radical " refers to the unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent of saturation or part, and it includes 3 to 20 rings
Atom, wherein one or more annular atoms are selected from nitrogen, oxygen or S (O)mThe hetero atom of (wherein m is integer 0 to 2), but do not wrap
- O-O- ,-O-S- or-S-S- loop section are included, remaining annular atom is carbon.3 to 12 annular atoms are preferably comprised, wherein 1~4
It is hetero atom;3 to 8 annular atoms are most preferably comprised, wherein 1~3 is hetero atom;5 to 6 annular atoms are most preferably comprised, its
In 1~2 or 1~3 be hetero atom.The non-limiting examples of monocyclic heterocycles base include pyrrolidinyl, imidazolidinyl, tetrahydrofuran
Base, THP trtrahydropyranyl, tetrahydro-thienyl, glyoxalidine base, dihydrofuran base, pyrazoline base, pyrrolin base, piperidyl,
Piperazinyl, morpholinyl, thio-morpholinyl, homopiperazine base etc., preferably THP trtrahydropyranyl, piperidyl, pyrrolidinyl.Multiring heterocyclic
Include the heterocyclic radical of loop coil, condensed ring and bridged ring.
Term " spiro heterocyclic radical " refers to the multiring heterocyclic that an atom (title spiro-atom) is shared between 5 to 20 yuan monocyclic
Group, wherein one or more annular atoms are selected from nitrogen, oxygen or S (O)mThe hetero atom of (wherein m is integer 0 to 2), remaining annular atom
For carbon.It can contain one or more double bonds, but neither one ring has the pi-electron system of total conjugated.Preferably 6 to 14
Member, more preferably 7 to 10 yuan.Spiro heterocyclic radical is divided into single spiro heterocyclic radical by the number according to spiro-atom is shared between ring and ring, double
Spiro heterocyclic radical or many spiro heterocyclic radicals, are preferably single spiro heterocyclic radical and double spiro heterocyclic radicals.More preferably 4 yuan/4 yuan, 4 yuan/5 yuan, 4
Member/6 yuan, 5 yuan/5 yuan or 5 yuan/6 yuan single spiro heterocyclic radicals.The non-limiting examples of spiro heterocyclic radical include:
Term " condensed hetero ring base " refers to each ring in 5 to 20 yuan, system and shared a pair adjoined of other rings in system
The polycyclic heterocyclic group of atom, one or more rings can contain one or more double bonds, but neither one ring is with completely common
The pi-electron system of yoke, wherein one or more annular atoms are selected from nitrogen, oxygen or S (O)mThe miscellaneous original of (wherein m is integer 0 to 2)
Son, remaining annular atom is carbon.Preferably 6 to 14 yuan, more preferably 7 to 10 yuan.According to composition ring number can be divided into it is bicyclic,
Three rings, Fourth Ring or polycyclic condensed hetero ring base, preferably bicyclic or three rings, more preferably 5 yuan/5 yuan or 5 yuan/6 membered bicyclic condensed hetero rings
Base.The non-limiting examples of condensed hetero ring base include:
Term " bridge heterocyclic radical " refers to 5 to 14 yuan, and any two ring shares the polycyclic heterocycle of two atoms being not directly connected
Group, it can contain one or more double bonds, but neither one ring has the pi-electron system of total conjugated, one of them or
Multiple annular atoms are selected from nitrogen, oxygen or S (O)mThe hetero atom of (wherein m is integer 0 to 2), remaining annular atom is carbon.Preferably 6
To 14 yuan, more preferably 7 to 10 yuan.Bicyclic, three rings, Fourth Ring or polycyclic bridge heterocyclic radical can be divided into according to the number of composition ring,
Preferably bicyclic, three rings or Fourth Ring, more preferably bicyclic or three rings.The non-limiting examples of bridge heterocyclic radical include:
The heterocyclic ring can be condensed on aryl, heteroaryl or cycloalkyl ring, wherein being connected to one with precursor structure
The ring risen is heterocyclic radical, and its non-limiting examples includes:
Deng.
Heterocyclic radical can be it is optionally substituted or non-substituted, when substituted, substituent be preferably it is one or more with
Lower group, its independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio group, alkyl amino, halogen, sulfydryl, hydroxyl, nitro,
Cyano group, cycloalkyl, Heterocyclylalkyl, aryl, heteroaryl, cycloalkyloxy, heterocyclylalkoxy groups, cycloalkylthio, heterocycle alkylthio group, oxo
Base, carboxyl or carboxylic acid ester groups.
Term " aryl ", which refers to, has 6 to 14 yuan of full carbon of the pi-electron system being conjugated monocyclic or fused polycycle (is namely shared
The ring of adjacent carbon atoms pair) group, preferably 6 to 10 yuan, more preferably 5 to 6 yuan, such as phenyl and naphthyl.The aryl rings can
To condense on heteroaryl, heterocyclic radical or cycloalkyl ring, wherein being aryl rings, its non-limit with the ring that precursor structure links together
Property example processed includes:
Aryl can be substitution or non-substituted, and when substituted, substituent is preferably one or more following groups,
It is independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio group, alkyl amino, halogen, sulfydryl, hydroxyl, nitro, cyano group, ring
Alkyl, Heterocyclylalkyl, aryl, heteroaryl, cycloalkyloxy, heterocyclylalkoxy groups, cycloalkylthio, heterocycle alkylthio group, carboxyl or carboxylic acid
Ester group.
Term " heteroaryl " refers to the heteroaromatic system comprising 1 to 4 hetero atom, 5 to 14 annular atoms, and wherein hetero atom is selected
From oxygen, sulphur and nitrogen.Heteroaryl is preferably 5 to 10 yuan, containing 1 to 3 hetero atom;More preferably 5 yuan or 6 yuan, containing 1 to 2 miscellaneous original
Son;It is preferred that such as imidazole radicals, furyl, thienyl, thiazolyl, pyrazolyl, oxazolyl, pyrrole radicals, tetrazole radical, pyridine radicals, phonetic
Piperidinyl, thiadiazoles, pyrazinyl etc., preferably imidazole radicals, pyrazolyl or pyrimidine radicals, thiazolyl;More preferably pyrazolyl.The heteroaryl
Basic ring can be condensed on aryl, heterocyclic radical or cycloalkyl ring, wherein be heteroaryl ring with the ring that precursor structure links together,
Its non-limiting examples includes:
Heteroaryl can be it is optionally substituted or non-substituted, when substituted, substituent be preferably it is one or more with
Lower group, its independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio group, alkyl amino, halogen, sulfydryl, hydroxyl, nitro,
Cyano group, cycloalkyl, Heterocyclylalkyl, aryl, heteroaryl, cycloalkyloxy, heterocyclylalkoxy groups, cycloalkylthio, heterocycle alkylthio group, carboxyl
Or carboxylic acid ester groups.
Term " alkoxy " refers to-O- (alkyl) and-O- (non-substituted cycloalkyl), wherein alkyl as defined above.Alcoxyl
The non-limiting examples of base include:Methoxyl group, ethyoxyl, propoxyl group, butoxy, ring propoxyl group, cyclobutoxy group, cyclopentyloxy,
Cyclohexyloxy.Alkoxy can be it is optionally substituted or non-substituted, when substituted, substituent be preferably it is one or more with
Lower group, its independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio group, alkyl amino, halogen, sulfydryl, hydroxyl, nitro,
Cyano group, cycloalkyl, Heterocyclylalkyl, aryl, heteroaryl, cycloalkyloxy, heterocyclylalkoxy groups, cycloalkylthio, heterocycle alkylthio group, carboxyl
Or carboxylic acid ester groups.
Term " amino protecting group " refers to suitable for the group that chemically reacts of protection (prevention) amino, but it molecule its
His position needs the chemical reaction carried out to be easily removed after terminating.The Typical Representative of these groups has unsubstituted or substituted
Acyl group, unsubstituted or substituted pi-allyl, aryl, Aralkoxymethyl, aralkyl form heterocyclic radical together with nitrogen-atoms
And salt.Non-limiting example includes tertbutyloxycarbonyl (Boc), benzyloxycarbonyl, isobutoxy carbonyl, fluorenylmethyloxycarbonyl
(Fmoc), benzoyl, the benzoyl of substitution, bytyry, acetyl group, trifluoroacetyl group, adjacent this dicarboximide base
(Pht), succinimide base, Maleimido, benzyl, allyloxycarbonyl and to methoxy-benzyl etc..These groups can appoint
Selection of land is selected from the substituted benzyl such as halogen, alkyl, alkoxy, hydroxyl, nitro, acyl amino, acyl group, adjacent methyl-benzyl, three
One or more substituents of benzyl and benzhydryl are replaced.The amino protecting group is preferably tertbutyloxycarbonyl and fluorenes first
Oxygen carbonyl (Fmoc).
Term " hydroxyalkyl " refers to the alkyl being optionally substituted by a hydroxyl group, wherein alkyl as defined above.
Term " haloalkyl " refers to alkyl and replaced by one or more halogens, and wherein alkyl is as defined above.
Term " hydroxyl " refers to-OH groups.
Term " halogen " refers to fluorine, chlorine, bromine or iodine.
Term " amino " refers to-NH2。
Term " cyano group " refers to-CN.
Term " nitro " refers to-NO2。
Term " carboxylic acid group " refers to-C (O) OH.
Term " carboxylic acid ester groups " refers to-C (O) O (alkyl) or-C (O) O (cycloalkyl), and wherein alkyl, cycloalkyl is as above determined
Justice.
Term " carboxylic acid halides " refers to the compound of the group containing-C (O)-halogen.
" X is selected from A, B or C ", " X is selected from A, B and C ", " X is A, B or C ", " X is that the different terms such as A, B and C " are expressed
Identical meaning, that is, it can be any one or a few in A, B, C to represent X.
" optional " or " optionally " mean event described later or environment can with but need not occur, the explanation includes
The occasion that the event or environment occur or do not occurred.For example, " optionally by alkyl-substituted heterocyclic group " means that alkyl can be with
But necessarily exist, the explanation includes heterocyclic group by alkyl-substituted situation and heterocyclic group not by alkyl-substituted situation.
" substituted " refers to one or more of group hydrogen atom, preferably at most 5, more preferably 1~3 hydrogen atom
Replaced independently of one another by the substituent of respective number.Self-evident, substituent is only in their possible chemical position, this
Art personnel can determine that (by experiment or theoretical) may or impossible take in the case where not paying excessive make great efforts
Generation.For example, amino or hydroxyl with free hydrogen are probably unstable when being combined with the carbon atom with unsaturated (such as olefinic) key
Fixed.
" pharmaceutical composition " represent containing one or more compounds described herein or its physiologically/pharmaceutically useful salt or
Pro-drug and the mixture of other chemical constituents, and other components such as physiology/pharmaceutically useful carrier and excipient.Medicine
The purpose of compositions is to promote the administration to organism, the absorption beneficial to active component and then performance bioactivity.
" officinal salt " refers to the salt of the compounds of this invention, and this kind of salt has security and had when being used in mammal body
Effect property, and with due bioactivity.
The synthetic method of the compounds of this invention
In order to complete the purpose of the present invention, the present invention is adopted the following technical scheme that:
Compound or its dynamic isomer, mesomer, racemic modification, enantiomter shown in the logical formula (I) of the present invention,
Diastereoisomer or its form of mixtures or its pharmaceutically useful salt production process, comprise the following steps:
Formula (I-1) compound is deprotected in acid condition obtains formula (I-2) compound or its salt, obtained formula
(I-2) compound or its salt reacts in the basic conditions with formula (I-3) compound, obtains formula (I-4) compound, obtains
Formula (I-4) compound sloughs the protection group on amino in the basic conditions, obtains formula (I-5) compound;Obtained formula
(I-5) with formula (I-6) compound condensation reaction occurs in the basic conditions for compound, obtains logical formula (IV) compound;Obtain
Logical formula (IV) further slough protection group in acid condition, obtain logical formula (I) compound or its salt.
There is provided the reagent of alkalescence condition includes organic base and inorganic base, and described organic bases include but is not limited to pyrrole
Pyridine, hexahydropyridine, triethylamine, N, N- diisopropylethylamine, n-BuLi, lithium diisopropylamine, potassium acetate, sodium tert-butoxide or
Potassium tert-butoxide, described inorganic base includes but is not limited to sodium hydride, potassium phosphate, sodium carbonate, potassium carbonate, cesium carbonate, hydroxide
Sodium and lithium hydroxide, preferably pyridine.
There is provided acid condition reagent include but is not limited to hydrogen chloride, trifluoroacetic acid, formic acid, acetic acid, hydrochloric acid, sulfuric acid and
Methanesulfonic acid, preferably hydrogen chloride or trifluoroacetic acid.
Condensing agent includes but is not limited to 1- (3- dimethylamino-propyls) -3- ethyl-carbodiimide hydrochlorides, N, the hexamethylenes of N'- bis-
Base carbodiimides, N, N'- diisopropylcarbodiimides, O- BTAs-N, N, N', N'- tetramethylurea tetrafluoro boric acid
Ester, I-hydroxybenzotriazole, 1- hydroxyl -7- azos BTA, O- BTAs-N, N, N', N'- tetramethylurea (TMU) hexafluoro phosphorus
Acid esters, 2- (7- oxidation BTA -1- bases)-N, N, N', N'- tetramethylurea hexafluorophosphoric acids ester, the 2- (nitrogen of 7- azos benzo three
Azoles)-N, N, N', N'- tetramethylurea hexafluorophosphoric acids ester, (dimethylamino) phosphorus hexafluoro phosphorus of BTA -1- bases epoxide three
Hydrochlorate or hexafluorophosphoric acid BTA -1- bases-epoxide tripyrrole alkyl phosphorus, preferably 2- (7- aoxidizes BTA)-N, N,
N', N'- tetramethylurea hexafluorophosphoric acid ester.
Above-mentioned reaction is preferably carried out in a solvent, and solvent for use includes but is not limited to:Acetic acid, methanol, ethanol, toluene, four
Hydrogen furans, dichloromethane, dimethyl sulfoxide (DMSO), 1,4- dioxane, water, N,N-dimethylformamide and its mixture.
Wherein:
W is amino protecting group;
G、R1And R2As defined in logical formula (I).
Embodiment
The present invention is further described with reference to embodiments, but these embodiments not limit the scope of the present invention.
Embodiment
The structure of compound is determined by nuclear magnetic resonance (NMR) or/and mass spectrum (MS).NMR displacements (δ) are with 10-6
(ppm) unit is provided.NMR measure is to use Bruker AVANCE-400 nuclear magnetic resonance spectrometers, and measure solvent is deuterated dimethyl sulfoxide
(DMSO-d6), deuterochloroform (CDCl3), deuterated methanol (CD3), OD inside it is designated as tetramethylsilane (TMS).
MS measure is with FINNIGAN LCQAd (ESI) mass spectrograph (manufacturer:Thermo, model:Finnigan LCQ
advantage MAX)。
HPLC measure uses Agilent 1200DAD high pressure liquid chromatographs (Sunfire C18 150 × 4.6mm chromatograms
Post) and Waters 2695-2996 high pressure liquid chromatographs (Gimini 150 × 4.6mm of C18 chromatographic columns).
Kinases average inhibition and IC50The measure of value is with NovoStar ELIASAs (German BMG companies).
Tlc silica gel plate uses Yantai Huanghai Sea HSGF254 or Qingdao GF254 silica gel plates, and thin-layered chromatography (TLC) makes
The specification that silica gel plate is used is 0.15mm~0.2mm, the specification that thin-layer chromatography isolates and purifies product use be 0.4mm~
0.5mm。
Column chromatography is carrier typically using the mesh silica gel of Yantai Huanghai Sea silica gel 200~300.
The known initiation material of the present invention can be used or synthesized according to methods known in the art, or can purchase certainly
ABCR GmbH&Co.KG, Acros Organics, Aldrich Chemical Company, splendid remote chemical science and technology (Accela
ChemBio Inc), up to companies such as auspicious chemicals.
Without specified otherwise in embodiment, reaction can be carried out under argon atmospher or blanket of nitrogen.
Argon atmospher or blanket of nitrogen refer to that reaction bulb connects the argon gas or nitrogen balloon of an about 1L volume.
Nitrogen atmosphere refers to that reaction bulb connects the hydrogen balloon of an about 1L volume.
Pressure hydration reaction uses Parr 3916EKX types hydrogenation instrument and clear indigo plant QL-500 types hydrogen generator or HC2-SS
Type hydrogenates instrument.
Hydrogenation is generally vacuumized, and is filled with hydrogen, is operated 3 times repeatedly.
Microwave reaction uses the type microwave reactors of CEM Discover-S 908860.
Without specified otherwise in embodiment, solution refers to the aqueous solution.
Without specified otherwise in embodiment, the temperature of reaction is room temperature, is 20 DEG C~30 DEG C.
The monitoring of reaction process in embodiment uses thin-layered chromatography (TLC), the system of solvent used in reaction
Have:A:Dichloromethane and methanol system, B:N-hexane and ethyl acetate system, C:Petroleum ether and ethyl acetate system, D:Acetone,
The volume ratio of solvent is adjusted according to the polarity difference of compound.The body of the eluant, eluent for the column chromatography that purifying compound is used
The solvent system of system and thin-layered chromatography includes:A:Dichloromethane and methanol system, B:N-hexane and ethyl acetate system, C:
Dichloromethane and acetone system, the volume ratio of solvent are adjusted according to the polarity difference of compound, can also add a small amount of
Triethylamine and the alkalescence such as acetic acid or acid reagent be adjusted.
Embodiment 1
(R)-N- ((R) -6- amino -1- (4- (3- methyl urea groups) piperidin-1-yl) -1- oxohexane -2- bases) -2-
((R) -2- ((R) -2- amino -3- phenylpropionyls amido) -3- phenylpropionyls amido) -4- methylpentanamides 1
The first step
4- ((phenyloxycarbonyl) amino) piperidines -1- t-butyl formates 1b
By 4- amino piperidine -1- t-butyl formates 1a (0.5g, 2.5mmol), pyridine (0.22g, 2.75mmol) is dissolved in
In 15mL tetrahydrofurans, phenyl chloroformate (0.43g, 2.75mmol) is added dropwise at 0 DEG C, reaction solution is warmed to room temperature, and stirring reaction 2 is small
When.Reaction solution is concentrated under reduced pressure, and residue adds ethyl acetate dissolving, is washed with water, anhydrous sodium sulfate drying, filters, and filtrate subtracts
Pressure concentration, obtains crude title product 1b (0.9g), the not purified direct carry out the next step of product.
Second step
4- (3- methyl urea groups) piperidines -1- t-butyl formates 1c
Crude product 1b (0.9g, 2.5mmol) is dissolved in 20mL methanol, the tetrahydrofuran for adding 1.3mL 2M methylamines is molten
Liquid, stirring reaction 12 hours at 50 DEG C.Reaction solution is cooled to room temperature, is concentrated under reduced pressure, pure with solvent system A with thin-layered chromatography
Change gained residue, obtain title product 1c (0.35g, yield:55%).
MS m/z(ESI):256.1[M-1]
3rd step
1- methyl -3- (piperidin-4-yl) urea hydrochloride 1d
1c (0.35g, 1.36mmol) is dissolved in 5mL dichloromethane, Isosorbide-5-Nitrae-dioxy six of 1mL 4M hydrogen chloride is added
Ring solution, stirring reaction 2 hours.Reaction solution is concentrated under reduced pressure, and obtains crude title product 1d (0.3g), and product is not purified directly
Carry out next step reaction.
4th step
(R)-(9H- fluorenes -9- bases) methyl tertbutyl (6- (4- (3- methyl urea groups) piperidin-1-yl) -6- oxohexane -1,
5- diyls) diurethane 1f
By crude product 1d (0.3g, 1.36mmol), (R) -2- ((((9H- fluorenes -9- bases) methoxyl group) carbonyl) amino) -6- ((uncles
Butoxy carbonyl) amino) caproic acid 1e (and 637mg, 1.36mmol, using known method " Tetrahedron, 2002,58 (27),
5427-5439 " is prepared) it is dissolved in 5mL DMFs, add 2- (7- azo phenylpropyl alcohol triazoles -1-
Base)-N, N, N', N'- tetramethylurea hexafluorophosphoric acid esters (0.775g, 2.04mmol), triethylamine (0.38mL, 2.72mmol) stirs
Mix reaction 12 hours.Reaction solution is concentrated under reduced pressure, with thin-layered chromatography with solvent system A purify gained residue, obtain title
Product 1f (390mg, yield:47%).
MS m/z(ESI):608.2[M+1]
5th step
(R)-(5- amino -6- (4- (3- methyl urea groups) piperidin-1-yl) -6- oxo-hexyls) t-butyl carbamate 1g
1f (120mg, 0.197mmol) is dissolved in 5mL dichloromethane, 1mL hexahydropyridines are added, stirring reaction 12 is small
When.Reaction solution is concentrated under reduced pressure, with thin-layered chromatography with solvent system A purify gained residue, obtain 1g (76mg, yield:
100%).
MS m/z(ESI):386.2[M+1]
6th step
N- [(5R) -5- [(2R) -2- [(2R) -2- [(2R) -2- { [(tert-butoxy) carbonyl] amino } -3- Phenylpropionamides
Base] -3- phenylpropionyls amido] -4- methyl valeryls amido] -6- { 4- [(methylcarbamoyl) amino] piperidin-1-yl } -6-
Oxo-hexyl] t-butyl carbamate 1i
By 1g (76mg, 0.197mmol), (6R, 9R, 12R) -6,9- dibenzyl -12- isobutyl group -2,2- dimethyl -4,7,
10- trioxy- -3- oxa-s -5,8,11- tri- azepine tridecane -13- carboxylics 1h (104mg, 0.197mmol, using patent application
Method disclosed in " US20110212882 " is prepared), 2- (7- azo phenylpropyl alcohol triazole -1- bases)-N, N, N', N'- tetramethyls
Urea hexafluorophosphoric acid ester (112mg, 0.296mmol) and triethylamine (0.055mL, 0.394mmol) are dissolved in 5mL N, N- dimethyl
In formamide, stirring reaction 12 hours.Reaction solution is concentrated under reduced pressure, and it is remaining with solvent system A to purify gained with thin-layered chromatography
Thing, obtains title product 1i (100mg, yield:57%).
MS m/z(ESI):894.5[M+1]
7th step
(R)-N- ((R) -6- amino -1- (4- (3- methyl urea groups) piperidin-1-yl) -1- oxohexane -2- bases) -2-
((R) -2- ((R) -2- amino -3- phenylpropionyls amido) -3- phenylpropionyls amido) -4- methylpentanamides 1
1i (100mg, 0.112mmol) is dissolved in 5mL dichloromethane, 0.5mL trifluoroacetic acids, stirring reaction 2 is added
Hour.Reaction solution is concentrated under reduced pressure, with high performance liquid chromatography purify gained residue, obtain title product 1 (10mg, yield:
14%).
MS m/z(ESI):693.7[M+1]
1H NMR(400MHz,DMSO-d6):δ8.42(d,1H),8.19(d,1H),7.39-7.29(m,10H),7.22(d,
1H),6.10(s,1H),5.12(s,4H),4.73(d,1H),4.41-4.37(m,2H),4.09(d,1H),3.74(d,1H),
3.27-3.24(m,3H),3.02-2.96(m,4H),2.70(s,3H),2.16-1.90(m,2H),1.85-1.55(m,9H),
1.51-1.25(m,6H),1.00(d,3H),0.96(d,3H).
Embodiment 2
(R)-N- ((R) -6- amino -1- oxos -1- (4- (3- phenyl urea groups) piperidin-1-yl) hexane -2- bases) -2-
((R) -2- ((R) -2- amino -3- phenylpropionyls amido) -3- phenylpropionyls amido) -4- methylpentanamides 2
The first step
(R)-(9H- fluorenes -9- bases) methyl tertbutyl (6- oxos -6- (4- (3- phenyl urea groups) piperidin-1-yl) hexane -1,
5- diyls) diurethane 2b
By 1e (3.1g, 6.5mmol), 1- phenyl -3- (piperidin-4-yl) ureas 2a (1.44g, 6.5mmol, using patent Shen
Please method disclosed in " EP628310 " is prepared) it is dissolved in 50mL DMFs, add 2- (7- azobenzenes
Third triazole -1- bases)-N, N, N', N'- tetramethylurea hexafluorophosphoric acid esters (3.77g, 9.9mmol), triethylamine (2g, 20mmol),
Stirring reaction 12 hours.Reaction solution is concentrated under reduced pressure, and obtains crude title product 2b (4.43g), and product is not purified directly to be carried out
The next step.
Second step
(R)-(5- amino -6- oxos -6- (4- (3- phenyl urea groups) piperidin-1-yl) hexyl) t-butyl carbamate 2c
Crude product 2b (4.43g, 6.5mmol) is dissolved in 20mL dichloromethane, 6mL hexahydropyridines, stirring reaction 2 is added
Hour.Reaction solution is concentrated under reduced pressure, with silica gel column chromatography method with eluant, eluent system A purify gained residue, obtain 2c (2.96g,
Yield:100%).
3rd step
N- [(5R) -5- [(2R) -2- [(2R) -2- [(2R) -2- { [(tert-butoxy) carbonyl] amino } -3- Phenylpropionamides
Base] -3- phenylpropionyls amido] -4- methyl valeryls amido] -6- oxos -6- { 4- [(phenylcarbamoyl) amino] piperidines -1-
Base } hexyl] t-butyl carbamate 2d
By 2c (200mg, 0.44mmol), 1h (235mg, 0.44mmol), 2- (7- azo phenylpropyl alcohol triazole -1- bases)-N,
N, N', N'- tetramethylurea hexafluorophosphoric acid ester (255mg, 0.67mmol) and triethylamine (135mg, 1.3mmol) are dissolved in 10mL
In DMF, stirring reaction 12 hours.Reaction solution is concentrated under reduced pressure, and obtains crude title product 2d (427mg), production
The not purified direct carry out the next step of product.
MS m/z(ESI):955.7[M+1]
4th step
(R)-N- ((R) -6- amino -1- oxos -1- (4- (3- phenyl urea groups) piperidin-1-yl) hexane -2- bases) -2-
((R) -2- ((R) -2- amino -3- phenylpropionyls amido) -3- phenylpropionyls amido) -4- methylpentanamides 2
Crude product 2d (427mg, 0.44mmol) is dissolved in 10mL dichloromethane, 2mL trifluoroacetic acids, stirring reaction is added
2 hours.Reaction solution is concentrated under reduced pressure, with high performance liquid chromatography purify gained residue, obtain title product 2 (15mg, yield
4.5%).
MS m/z(ESI):755.4[M+1]
1H NMR(400MHz,CD3OD)δ7.34-7.21(m,13H),7.18-6.96(m,2H),4.68-4.61(m,2H),
4.38-4.25(m,3H),4.08-4.00(m,1H),3.83-3.71(m,2H),3.70-3.55(m,2H),3.21-3.07(m,
3H),3.06-2.63(m,6H),2.75-2.56(m,2H),1.82-1.73(m,2H),1.72-1.56(m,6H),1.52-1.38
(m,4H),1.32-1.25(m,2H),0.98-0.91(m,6H),0.75-0.67(m,2H).
Embodiment 3
(R)-N- ((R) -6- amino -1- (4- (N- Methylsulfamoyls amino) piperidin-1-yl) -1- oxohexanes -2-
Base) -2- ((R) -2- ((R) -2- amino -3- phenylpropionyls amido) -3- phenylpropionyls amido) -4- methylpentanamides 3
The first step
4- ((N- Methylsulfamoyls) amino) piperidines -1- t-butyl formates 3a
By 1a (113mg, 0.56mmol), pyridine (66mg, 0.84mmol) is dissolved in 5mL dichloromethane, is added dropwise at 0 DEG C
The dichloromethane solution of 5mL meth vlsulfonamides chlorine (80mg, 0.62mmol), reaction solution is warmed to room temperature, stirring reaction 12 hours.Instead
Answer liquid to add dichloromethane, be washed with water, anhydrous sodium sulfate drying, filter, filtrate decompression concentration obtains crude title product 3a
(164mg), the not purified direct carry out the next step of product.
Second step
Methyl [(piperidin-4-yl) sulfamoyl] amine hydrochlorate 3b
Crude product 3a (164mg, 0.559mmol) is dissolved in 5mL dichloromethane, the Isosorbide-5-Nitrae-two of 1mL 4M hydrogen chloride is added
The ring solution of oxygen six, stirring reaction 2 hours.Reaction solution is concentrated under reduced pressure, and obtains crude title product 3b (128mg), product is without pure
Change and directly carry out the next step.
3rd step
(R)-(5- amino -6- (4- ((N- Methylsulfamoyls) amino) piperidin-1-yl) -6- oxo-hexyls) carbamic acid
Tert-butyl ester 3c
By crude product 3b (120mg, 0.559mmol), 1e (290mg, 0.62mmol) is dissolved in 20mL N, N- dimethyl formyls
In amine, addition 2- (7- azo phenylpropyl alcohol triazole -1- bases)-N, N, N', N'- tetramethylurea hexafluorophosphoric acids ester (343mg,
0.9mmol) with 3mL triethylamines, stirring reaction 12 hours.Reaction solution is concentrated under reduced pressure, and residue adds ethyl acetate, and washing has
Machine mutually uses anhydrous sodium sulfate drying, and filtering, filtrate decompression concentration obtains crude title product 3c (261mg), product is not purified
Directly carry out the next step.
4th step
N- [(5R) -5- [(2R) -2- [(2R) -2- [(2R) -2- { [(tert-butoxy) carbonyl] amino } -3- Phenylpropionamides
Base] -3- phenylpropionyls amido] -4- methyl valeryls amido] -6- { 4- [(Methylsulfamoyl) amino] piperidin-1-yl } -6- oxygen
For hexyl] t-butyl carbamate 3d
By crude product 3c (261mg, 0.559mmol), 1h (325mg, 0.62mmol), 2- (7- azo phenylpropyl alcohol triazoles -1-
Base)-N, N, N', N'- tetramethylurea hexafluorophosphoric acid esters (342mg, 0.9mmol) and triethylamine (1mL, 1.24mmol) are dissolved in
In 20mL DMFs, stirring reaction 12 hours.Reaction solution is concentrated under reduced pressure, with thin-layered chromatography with solvent body
It is A purifying gained residues, obtains title product 3d (300mg, yield:55.4%).
MS m/z(ESI):929.5[M+1]
5th step
(R)-N- ((R) -6- amino -1- (4- (N- Methylsulfamoyls amino) piperidin-1-yl) -1- oxohexanes -2-
Base) -2- ((R) -2- ((R) -2- amino -3- phenylpropionyls amido) -3- phenylpropionyls amido) -4- methylpentanamides 3
3d (300mg, 0.323mmol) is dissolved in 10mL dichloromethane, Isosorbide-5-Nitrae-dioxy of 1mL 4M hydrogen chloride is added
Six ring solution, stirring reaction 1 hour.Reaction solution is concentrated under reduced pressure, with high performance liquid chromatography purify gained residue, obtain title
Product 3 (20mg, yield:9%).
MS m/z(ESI):729.4[M+1]
1H NMR(400MHz,CD3OD)δ8.46(s,1H),8.21(s,1H),7.33-7.24(m,10H),4.73-4.46
(m, 4H), 4.12-3.75 (m, 4H), 3.75-3.71 (m, 1H), 3.24-2.95 (m, 9H), 2.67-2.56 (m, 3H), 1.99-
1.81(m,3H),1.71-1.45(m,7H),1.39-1.33(m,7H),0.99(d,6H).
Embodiment 4
(R) -2- ((R) -2- ((R) -2- amino -3- phenylpropionyls amido) -3- phenylpropionyls amido) -4- methyl-N-
((R) -1- (4- (3- methyl urea groups) piperidin-1-yl) -1- oxos -3- (piperidin-4-yl epoxide) propane -2- bases) pentanamide 4
The first step
(R) -4- (2- (tertbutyloxycarbonylamino) -3- methoxyl group -3- oxopropoxies) piperidines -1- benzyl formates 4c
By 4- hydroxy piperidine -1- benzyl formates 4b (1.31g, 5.57mmol, using known method " Heterocycles,
2009,77 (1), 417-432 " is prepared) it is dissolved in 30mL dichloromethane, 0 DEG C is cooled to, BFEE is added
(97 μ L, 0.77mmol), stirring reaction 10 minutes.Add 5mL (S) -1- tert-butyl group 2- methyl-aziridinyl propyl group -1,2- diformazans
Acid esters 4a (773mg, 3.85mmol, using known method " OrganicLetters, 11 (23), 5558-5561;2009 " systems
It is standby and obtain) dichloromethane solution, stirring reaction 1 hour.It is warmed to room temperature, stirring reaction 15 hours.Add 1M sodium hydroxides molten
Liquid, is extracted with dichloromethane, anhydrous sodium sulfate drying, filtering, filtrate decompression concentration, with silica gel column chromatography with eluant, eluent system
A purifying gained residues, obtain title product 4c (0.63g, yield 38%).
MS m/z(ESI):337.2[M-100]
Second step
(R) -3- (1- (benzyloxycarbonyl) piperidin-4-yls epoxide) -2- (tertbutyloxycarbonylamino) propionic acid 4d
4c (1.39g, 3.18mmol) is dissolved in 20mL tetrahydrofurans, first alcohol and water (V:V:V=4:4:1) mixing is molten
In agent, lithium hydroxide (670mg, 15.9mmol), stirring reaction 15 hours are added.The hydrochloric acid regulation reaction solution pH that 2M is added dropwise is 2,
It is extracted with ethyl acetate (15mL × 3), saturated nacl aqueous solution (15mL × 3) washing, anhydrous sodium sulfate drying, filtering, filtrate
It is concentrated under reduced pressure, obtains crude title product 4d (1.05g, yield 78%).
MS m/z(ESI):413.2[M+1]
3rd step
1- methyl -3- (piperidin-4-yl) urea 2,2,2- trifluoroacetates 4e
1c (0.15g, 0.584mmol) is dissolved in 5mL dichloromethane, 1mL trifluoroacetic acids are added, stirring reaction 2 is small
When.Reaction solution is concentrated under reduced pressure, and obtains crude title product 4e (0.158g), and product is not purified directly to carry out next step reaction.
4th step
(R) -4- (2- ((tert-butoxycarbonyl) amino) -3- (4- (3- methyl urea groups) piperidin-1-yl) third oxygen of -3- oxos
Base) piperidines -1- benzyl formates 4f
Crude product 4d (247mg, 0.58mmol) and crude product 4e (158mg, 0.58mmol) are dissolved in 5mL N, N- dimethyl
In formamide, addition 2- (7- azo phenylpropyl alcohol triazole -1- bases)-N, N, N', N'- tetramethylurea hexafluorophosphoric acids ester (332mg,
0.876mmol), triethylamine (0.16mL, 1.17mmol), stirring reaction 12 hours.Reaction solution is concentrated under reduced pressure, and residue adds second
Acetoacetic ester, washing, anhydrous sodium sulfate drying, filtering, filtrate decompression concentration purifies institute with thin-layered chromatography with solvent system A
Residue is obtained, title product 4f (185mg, yield is obtained:56%).
5th step
(R) -4- (2- amino -3- (4- (3- methyl urea groups) piperidin-1-yl) -3- oxopropoxies) piperidines -1- formic acid benzyls
Ester 2,2,2- trifluoroacetates 4g
4f (185mg, 0.329mmol) is dissolved in 5mL dichloromethane, 1mL trifluoroacetic acids are added, stirring reaction 2 is small
When.Reaction solution is concentrated under reduced pressure, and obtains crude title product 4g (189mg), the not purified direct carry out the next step of product
6th step
4- (((6R, 9R, 12R, 15R) -6,9- dibenzyl -12- isobutyl group -2,2- dimethyl -15- (4- (3- MUs
Base) piperidines -1- carbonyls) four oxo -3- oxa-s -5,8,11,14- of -4,7,10,13-, four azepine hexadecane -16- bases) epoxide) piperazine
Pyridine -1- benzyl formates 4h
By crude product 4g (189mg, 0.329mmol), 1h (173mg, 0.329mmol), 2- (7- azo phenylpropyl alcohol triazoles -1-
Base)-N, N, N', N'- tetramethylurea hexafluorophosphoric acid esters (188mg, 0.494mmol) and triethylamine (0.092mL, 0.658mmol)
It is dissolved in 5mL DMFs, stirring reaction 12 hours.Reaction solution is concentrated under reduced pressure, and residue adds acetic acid second
Ester, washing, anhydrous sodium sulfate drying, filtering, filtrate decompression concentration, with thin-layered chromatography with solvent system A purify obtained by it is residual
Excess, obtains title product 4h (146mg, yield:46%).
MS m/z(ESI):969.6[M+1]
7th step
((R) -1- (((R) -1- (((R) -4- methyl isophthalic acids-(((R) -1- (4- (3- methyl urea groups) piperidin-1-yl) -1- oxygen
Generation -3- (piperidin-4-yl epoxide) propane -2- bases) amino) -1- oxo-pentane -2- bases) amino) -1- oxo -3- phenyl-propanes -
2- yls) amino) -1- oxo -3- phenyl-propane -2- bases) t-butyl carbamate 4i
4h (146mg, 0.151mmol) is dissolved in 15mL methanol, palladium/carbon (20mg, 10%), hydrogen displacement three is added
It is secondary, stirring reaction 12 hours.Reacting liquid filtering, filtrate decompression concentration, obtains crude title product 4i (126mg), product without
Purifying directly carries out the next step
MS m/z(ESI):935.6[M+1]
8th step
(R) -2- ((R) -2- ((R) -2- amino -3- phenylpropionyls amido) -3- phenylpropionyls amido) -4- methyl-N-
((R) -1- (4- (3- methyl urea groups) piperidin-1-yl) -1- oxos -3- (piperidin-4-yl epoxide) propane -2- bases) pentanamide 4
Crude product 4i (126mg, 0.151mmol) is dissolved in 5mL dichloromethane, 1mL trifluoroacetic acids, stirring reaction is added
2 hours.Reaction solution is concentrated under reduced pressure, with high performance liquid chromatography purify gained residue, obtain title product 4 (45mg, yield
40%).
MS m/z(ESI):735.4[M+1]
1H NMR(400MHz,DMSO-d6):δ8.40(d,1H),8.36(d,1H),8.03(s,3H),7.21-7.40(m,
10H),5.10-5.16(m,2H),4.70-4.75(m,1H),4.38-4.51(m,2H),4.07-4.10(m,2H),3.85-
3.95(m,2H),3.71-3.78(m,4H),3.20-3.33(m,5H),3.05-3.15(m,2H),2.85-3.04(m,4H),
2.67(d,3H),1.82-2.05(m,6H),1.55-1.77(m,4H),1.00(d,3H),0.95(d,3H).
Embodiment 5
(R) -2- ((R) -2- ((R) -2- amino -3- phenylpropionyls amino) -3- phenylpropionyls amino) -4- methyl-N-
((R) -1- (4- (3- methyl urea groups) piperidin-1-yl) -1- oxos -3- ((S)-nafoxidine -2- ylmethoxies) propane -2- bases)
Pentanamide 5
The first step
(S) -2- (((R) -2- ((tert-butoxycarbonyl) amino) -3- methoxyl group -3- oxopropoxies) methyl) pyrrolidines -
1- benzyl formates 5c
By (S) -2- (hydroxymethyl) pyrrolidines -1- benzyl carboxylates 5b (0.88g, 3.73mmol, using known method
" Synthesis, 2013,45 (17), 2458-2468 " is prepared) it is dissolved in 10mL dichloromethane, it is cooled to 0 DEG C, addition
Boron trifluoride ether solution (63 μ L, 498 μm of ol), stirring reaction 10 minutes adds 10mL (S) -1- tert-butyl group 2- methyl ring second
Imines -1,2- dicarboxylic ester 5a (0.5g, 2.49mmol, using known method " Organic Letters, 2009,11 (23),
5558-5561 " is prepared) dichloromethane solution, 0 DEG C of stirring reaction 1 hour is warming up to room temperature, stirring reaction 16 hours.
20mL 1M sodium hydroxide solutions are added in reaction solution, are stirred 15 minutes, stratification, organic phase, aqueous phase ethyl acetate is separated
Extraction, merges organic phase, and anhydrous slufuric acid is dried, filtering, and filtrate decompression concentration is purified with silica gel column chromatography with eluent system A
Gained residue, obtains title product 5c (0.61g, yield:56%).
Second step
(R) -3- (((S) -1- ((benzyloxy) carbonyl) nafoxidine -2- bases) methoxyl group) -2- ((tert-butoxycarbonyl) ammonia
Base) propionic acid 5d
5c (0.61g, 1.4mmol) is dissolved in 18mL tetrahydrofurans, first alcohol and water (V/V/V=4:4:1) mixed solvent
In, a hydronium(ion) lithia (11.7mg, 2.8mmol) is added, reaction 16 hours is stirred at room temperature.Reaction solution pressurization concentration,
It is 2 that 1M hydrochloric acid is added dropwise in residue to pH, and ethyl acetate extraction, organic phase anhydrous sodium sulfate drying, filtering, filtrate decompression is dense
Contracting, obtains crude title product 5d (0.6g), and product is not purified directly to carry out next step reaction.
3rd step
(S) -2- (((R) -2- ((tert-butoxycarbonyl) amino) -3- (4- (3- methyl urea groups) piperidin-1-yl) -3- oxos
Propoxyl group) methyl) pyrrolidines -1- benzyl formates 5e
By crude product 5d (0.1g, 237 μm of ol), crude product 4e (70mg, 253 μm of ol), 2- (7- azo phenylpropyl alcohol triazoles -1-
Base)-N, N, N', N'- tetramethylurea hexafluorophosphoric acids ester (135mg, 356 μm of ol), triethylamine (66 μ L) and 3mLN, N- dimethyl methyl
Acid amides is added in reaction bulb, and reaction 16 hours is stirred at room temperature.Reaction solution is concentrated under reduced pressure, with silica gel column chromatography with eluent system
A purifying gained residues, obtain title product 5e (150mg, yield:100%).
4th step
(S) -2- (((R) -2- amino -3- (4- (3- methyl urea groups) piperidin-1-yl) -3- oxopropoxies) methyl) pyrroles
Alkane -1- benzyl formate trifluoroacetates 5f
5e (150mg, 237 μm of ol), 1mL trifluoroacetic acids are dissolved in 5mL dichloromethane, reaction 2 hours is stirred at room temperature.Instead
Answer liquid to be concentrated under reduced pressure, obtain crude title product 5f (140mg), product is not purified directly to carry out next step reaction.
5th step
(S) -2- ((4R, 7R, 10R, 13R) -10,13- dibenzyl -7- isobutyl group -17,17- dimethyl -4- (4- (3- first
Base urea groups) piperidines -1- carbonyls) four oxo -2,16- dioxas -5,8,11,14- of -6,9,12,15-, four azepine octadecyls) pyrrole
Cough up alkane -1- benzyl formates 5g
By crude product 5f (140mg, 0.237mmol), 1h (124mg, 0.237mmol), 2- (7- azo phenylpropyl alcohol triazoles -1-
Base)-N, N, N', N'- tetramethylurea hexafluorophosphoric acid esters (135mg, 0.356mmol) and triethylamine (66 μ L, 0.474mmol) dissolve
In 5mL DMFs, stirring reaction 12 hours.Reaction solution is concentrated under reduced pressure, with thin-layered chromatography with solvent body
It is A purifying gained residues, obtains title product 5g (240mg, yield:100%).
6th step
((4R, 7R, 10R, 13R) -10- benzyl -7- isobutyl groups -4- (4- (3- methyl urea groups) piperidines -1- carbonyls) -6,9,
The azepine tetradecane -13- the bases of 12- trioxy- -14- phenyl -1- ((S)-nafoxidine -2- bases) -2- oxa-s -5,8,11- three) amino
T-butyl formate 5h
5g (240mg, 0.237mmol) is dissolved in 15mL methanol, palladium carbon (30mg, 10%) is added, hydrogen is replaced three times,
Stirring reaction 4 hours.Reacting liquid filtering, filtrate decompression concentration, obtains crude title product 5h (220mg), product is not purified
Directly carry out next step reaction.
MS m/z(ESI):835.4[M+1]
7th step
(R) -2- ((R) -2- ((R) -2- amino -3- phenylpropionyls amino) -3- phenylpropionyls amino) -4- methyl-N-
((R) -1- (4- (3- methyl urea groups) piperidin-1-yl) -1- oxos -3- ((S)-nafoxidine -2- ylmethoxies) propane -2- bases)
Pentanamide 5
Crude product 5h (220mg, 0.237mmol) is dissolved in 5mL dichloromethane, 1mL trifluoroacetic acids, stirring reaction 2 is added
Hour.Reaction solution is concentrated under reduced pressure, with high performance liquid chromatography purify gained residue, obtain title product 5 (30mg, yield:
17%).
MS m/z(ESI):735.4[M+1]
1H NMR(400MHz,DMSO-d6):δ8.46(d,2H),8.30(t,3H),7.22-7.41(m,12H),5.05-
5.20(m,1H),4.72-4.76(m,1H),4.39-4.46(m,1H),4.05-4.11(m,1H),3.58-3.85(m,8H),
3.19-3.31(m,5H),2.93-3.04(m,3H),2.70(s,3H),1.85-2.18(m,6H),1.55-1.84(m,4H),
1.22-1.50(m,2H),1.01(d,3H),0.97(d,3H).
Embodiment 6
(R)-N- ((R) -6- amino -1- oxos -1- (4- (aminosulfonylamino) piperidin-1-yl) hexane -2- bases) -2-
((R) -2- ((R) -2- amino -3- phenylpropionyls amino) -3- phenylpropionyls amino) -4- methylpentanamides 6
The first step
(R)-(9H- fluorenes -9- bases) methyl tertbutyl (6- oxos -6- (4- (aminosulfonylamino) piperidin-1-yl) oneself
Alkane -1,5- diyls) diurethane 6b
By N- (piperidin-4-yl) sulfamides 6a (1g, 3mmol, using known method " Bioorganic&
Medicinal Chemistry Letters, 2009,19 (12), 3339-3343 " are prepared), 1e (1.4g, 3mmol) is molten
Solution adds 2- (7- azo phenylpropyl alcohol triazole -1- bases)-N, N, N', N'- tetramethylureas in 20mL DMFs
Hexafluorophosphoric acid ester (2.3g, 6mmol) and triethylamine (600mg, 6mmol), stirring reaction 12 hours.Reaction solution is concentrated under reduced pressure, plus
Enter 10mL citric acids saturated solution and 100mL water, be extracted with ethyl acetate, organic phase anhydrous sodium sulfate drying, filtering, filtrate
Be concentrated under reduced pressure, with thin-layered chromatography with solvent system A purify gained residue, obtain title product 6b (630mg, yield:
100%).
Second step
(R)-(5- amino -6- oxos -6- (4- (aminosulfonylamino) piperidin-1-yl) hexyl) t-butyl carbamate
6c
6b (630mg, 1mmol) is dissolved in 1mL DMFs, 3mL triethylamines, stirring reaction is added
12 hours.Reaction solution is concentrated under reduced pressure, and obtains crude title product 6c (407mg), and the not purified directly progress next step of product is anti-
Should.
3rd step
N- [(5R) -5- [(2R) -2- [(2R) -2- [(2R) -2- { [(tert-butoxy) carbonyl] amino } -3- phenylpropionyl ammonia
Base] -3- phenylpropionyls amino] -4- methylpentanoylaminos] and -6- oxos -6- (4- (aminosulfonylamino) piperidin-1-yl) oneself
Base) t-butyl carbamate 6d
By crude product 6c (420mg, 1mmol), 1h (530mg, 1mmol), 2- (7- azo phenylpropyl alcohol triazole -1- bases)-N, N,
N', N'- tetramethylurea hexafluorophosphoric acid ester (760mg, 2mmol) are dissolved in 5mL DMFs, stirring reaction 12
Hour.Reaction solution is concentrated under reduced pressure, and adds 10mL citric acids saturated solution and 100mL water, is extracted with ethyl acetate, organic phase is successively
With saturated sodium bicarbonate solution, saturated nacl aqueous solution washing, anhydrous sodium sulfate drying, filtering, filtrate decompression concentration obtains thick
Product title product 6d (460mg), product is not purified directly to carry out next step reaction.
MS m/z(ESI):915.6[M+1]
4th step
(R)-N- ((R) -6- amino -1- oxos -1- (4- (aminosulfonylamino) piperidin-1-yl) hexane -2- bases) -2-
((R) -2- ((R) -2- amino -3- phenylpropionyls amino) -3- phenylpropionyls amino) -4- methylpentanamide trifluoroacetates 6e
Crude product 6d (460mg, 0.5mmol) is dissolved in 10mL dichloromethane, 4mL trifluoroacetic acids, stirring reaction 3 is added
Hour.Reaction solution is concentrated under reduced pressure, with high performance liquid chromatography purify gained residue, obtain title product 6e (40mg, yield:
15%).
MS m/z(ESI):715.2[M+1]
1H NMR(400MHz,DMSO-d6)δ8.50-8.47(m,2H),8.44-8.40(m,2H),7.46-7.23(m,
10H),6.01-5.95(m,5H),5.11-5.07(m,2H),4.74-4.72(m,1H),4.37-4.30(m,2H),4.05-
3.99(m,2H),3.83-3.79(m,1H),3.28-2.92(m,8H),2.20-1.75(m,13H),0.99-0.95(m,6H).
5th step
(R)-N- ((R) -6- amino -1- oxos -1- (4- (aminosulfonylamino) piperidin-1-yl) hexane -2- bases) -2-
((R) -2- ((R) -2- amino -3- phenylpropionyls amino) -3- phenylpropionyls amino) -4- methylpentanamides 6
6e (40mg, 0.042mmol) is dissolved in 2mL dichloromethane and methanol (V:V=10:1) mixed solution dissolved clarification,
Saturated aqueous sodium carbonate regulation pH to 7 or so is added dropwise, stirring reaction 30 minutes, static layering, collect organic phase, nothing at room temperature
Water magnesium sulfate is dried, filtering, filtrate decompression concentration, obtains title product 6 (30mg, yield:99%).
MS m/z(ESI):715.2[M+1]
Embodiment 7
(R)-N- ((R) -6- amino -1- oxos -1- (4- Ureidopiperidine -1- bases) hexane -2- bases) -2- ((R) -2- ((R) -
2- amino -3- phenylpropionyls amino) -3- phenylpropionyls amino) -4- methylpentanamides 7
The first step
(R)-(9H- fluorenes -9- bases) methyl tertbutyl (6- oxos -6- (4- Ureidopiperidine -1- bases) hexane -1,5- diyls) two
Carbamate 7b
By 1e (637mg, 1.36mmol), 1- (piperidin-4-yl) urea 7a (441mg, 2.04mmol, using patent application
Method disclosed in " DE2609289 " is prepared) it is dissolved in 15mL DMFs, add 2- (7- azobenzenes third
Triazole -1- bases)-N, N, N', N'- tetramethylurea hexafluorophosphoric acid esters (775.2mg, 2.04mmol) and DIPEA
(0.7mL, 4.08mmol), stirring reaction 12 hours.Reaction solution is concentrated under reduced pressure, and is purified with thin-layered chromatography with solvent system A
Gained residue, obtains title product 7b (500mg, yield:62%).
Second step
(R)-(5- amino -6- oxos -6- (4- Ureidopiperidine -1- bases) hexyl) t-butyl carbamate 7c
7b (500mg, 0.84mmol) is dissolved in 5mL dichloromethane, 5mL hexahydropyridines are added, stirring reaction 12 is small
When.Reaction solution is concentrated under reduced pressure, with thin-layered chromatography with solvent system A purify gained residue, obtain title product 7c
(300mg, yield:96%).
3rd step
N- [(5R) -5- [(2R) -2- [(2R) -2- [(2R) -2- { [(tert-butoxy) carbonyl] amino } -3- phenylpropionyl ammonia
Base] -3- phenylpropionyls amino] -4- methylpentanoylaminos] -6- [4- (carbamoylamino) piperidin-1-yl] -6- oxo-hexyls]
T-butyl carbamate 7d
By 7c (300mg, 0.81mmol), 1h (424mg, 0.81mmol), 2- (7- azo phenylpropyl alcohol triazole -1- bases)-N,
N, N', N'- tetramethylurea hexafluorophosphoric acid ester (462mg, 1.2mmol) and DIPEA (0.3mL, 1.62mmol) are molten
Solution is in 10mL DMFs, stirring reaction 12 hours.Reaction solution is concentrated under reduced pressure, with thin-layered chromatography method to open up
Agent system A purifying gained residues are opened, title product 7d (300mg, yield is obtained:42%).
MS m/z(ESI):879.6[M+1]
4th step
(R)-N- ((R) -6- amino -1- oxos -1- (4- Ureidopiperidine -1- bases) hexane -2- bases) -2- ((R) -2- ((R) -
2- amino -3- phenylpropionyls amino) -3- phenylpropionyls amino) -4- methylpentanamide trifluoroacetates 7e
7d (300mg, 0.34mmol) is dissolved in 5mL dichloromethane, 5mL trifluoroacetic acids are added, stirring reaction 3 is small
When.Reaction solution is concentrated under reduced pressure, with high performance liquid chromatography purify gained residue, obtain title product 7e (120mg, yield:
52%).
MS m/z(ESI):679.6[M+1]
1H NMR(400MHz,DMSO-d6)δ7.39-7.22(m,10H),4.88-4.87(m,1H),4.73-4.71(m,
1H),4.43-4.359(m,2H),4.12-4.10(m,1H),4.05-3.90(m,1H),3.81-3.78(m,1H),3.77-
3.76(m,2H),3.28-3.21(m,3H),3.00-2.95(m,5H),2.46-2.44(m,1H),2.04-1.90(m,2H),
1.72-1.47(m,12H),1.00-0.95(m,6H),0.98-0.96(m,6H).
5th step
(R)-N- ((R) -6- amino -1- oxos -1- (4- Ureidopiperidine -1- bases) hexane -2- bases) -2- ((R) -2- ((R) -
2- amino -3- phenylpropionyls amino) -3- phenylpropionyls amino) -4- methylpentanamides 7
7e (120mg, 0.132mmol) is dissolved in 5mL dichloromethane and methanol (V:V=10:1) mixed solution is molten
Clearly, saturated aqueous sodium carbonate regulation pH to 7 or so is added dropwise, stirring reaction 30 minutes, static layering, are collected organic at room temperature
Phase, anhydrous magnesium sulfate is dried, filtering, filtrate decompression concentration, obtains title product 7 (90mg, yield:100%).
MS m/z(ESI):679.6[M+1]
Embodiment 8
((R) -5- ((R) -2- ((R) -2- ((R) -2- amino -3- phenylpropionyls amino) -3- phenylpropionyls amino) -4- first
Base valeryl amino) -6- (4- (3- methyl urea groups) piperidin-1-yl) -6- oxo-hexyls) methyl carbamate 8
The first step
(R)-benzyl tert-butyl group (6- (4- (3- methyl urea groups) piperidin-1-yl) -6- oxohexane -1,5- diyls) diaminourea
Formic acid esters 8b
By crude product 1d (350mg, 1.31mmol), (R) -2- (((benzyloxy) carbonyl) amino) -6- ((tertbutyloxycarbonyl) ammonia
Base) caproic acid 8a (500mg, 1.31mmol are prepared using method disclosed in patent application " WO2009018549 ") is dissolved in
In 6mL DMFs, 2- (7- azo phenylpropyl alcohol triazole -1- bases)-N, N, N', N'- tetramethylurea hexafluoro phosphorus is added
Acid esters (0.74g, 1.965mmol) and DIPEA (0.685mL, 3.93mmol), stirring reaction 15 hours.Reaction
50mL ethyl acetate, successively with saturated ammonium chloride solution (20mL × 3), saturated sodium bicarbonate solution (20mL × 3) are added in liquid
With saturated nacl aqueous solution (20mL × 3) washing, anhydrous sodium sulfate drying, filtering, filtrate decompression concentration obtains crude title production
Thing 8b (1.05g), product is not purified directly to carry out next step reaction.
Second step
(R)-(6- amino -1- (4- (3- methyl urea groups) piperidin-1-yl) -1- oxohexane -2- bases) benzyq carbamate
Hydrochloride 8c
Crude product 8b (680mg, 1.31mmol) is dissolved in 7mL dichloromethane, add 3.25mL 4M hydrogen chloride Isosorbide-5-Nitrae-
Dioxane solution, stirring reaction 3 hours.Reaction solution is concentrated under reduced pressure, and obtains crude title product 8c (1g), product is not purified
Directly carry out next step reaction.
3rd step
(R)-benzyl methyl (6- (4- (3- methyl urea groups) piperidin-1-yl) -6- oxohexane -1,5- diyls) diaminourea first
Acid esters 8d
Crude product 8c (137mg, 0.327mmol) is dissolved in 10mL dichloromethane, addition methylchloroformate (46mg,
0.49mmol) with triethylamine (110mg, 0.972mmol), stirring reaction 1 hour.30mL dichloromethane is added in reaction solution, according to
Secondary use saturated ammonium chloride solution (20mL × 3), saturated sodium bicarbonate solution (20mL × 3) and saturated nacl aqueous solution (20mL ×
3) wash, anhydrous sodium sulfate drying, filtering, filtrate decompression concentration obtains crude title product 8d (160mg), product is without pure
Change and directly carry out next step reaction.
4th step
(R)-(5- amino -6- (4- (3- methyl urea groups) piperidin-1-yl) -6- oxohexanes) methyl carbamate 8e
Crude product 8d (160mg, 0.327mmol) is dissolved in 5mL methanol, palladium carbon (40mg, 10%), hydrogen displacement three is added
It is secondary, stirring reaction 48 hours.Reacting liquid filtering, filtrate decompression concentration, obtains crude title product 8e (76mg), product is without pure
Change and directly carry out next step reaction.
5th step
N- [(5R) -5- [(2R) -2- [(2R) -2- [(2R) -2- { [(tert-butoxy) carbonyl] amino } -3- phenylpropionyl ammonia
Base] -3- phenylpropionyls amino] -4- methylpentanoylaminos) -6- { 4- [(methylcarbamoyl) amino] piperidin-1-yl } -6- oxygen
For hexyl] methyl carbamate 8f
By crude product 8e (77mg, 0.22mmol), 1h (110mg, 0.22mmol) is dissolved in 5mL DMFs
In, add 2- (7- azo phenylpropyl alcohol triazole -1- bases)-N, N, N', N'- tetramethylurea hexafluorophosphoric acid esters (125mg, 0.33mmol)
With DIPEA (85mg, 0.66mmol), stirring reaction 15 hours.50mL ethyl acetate is added in reaction solution, according to
Secondary use saturated ammonium chloride solution (20mL × 3), saturated sodium bicarbonate solution (20mL × 3) and saturated nacl aqueous solution (20mL ×
3) wash, anhydrous sodium sulfate drying, filtering, filtrate decompression concentration obtains crude title product 8f (187mg), product is without pure
Change and directly carry out next step reaction.
MS m/z(ESI):851.4[M+1]
6th step
((R) -5- ((R) -2- ((R) -2- ((R) -2- amino -3- phenylpropionyls amino) -3- phenylpropionyls amino) -4- first
Base valeryl amino) -6- (4- (3- methyl urea groups) piperidin-1-yl) -6- oxo-hexyls) methyl carbamate 8
Crude product 8f (187mg, 0.22mmol) is dissolved in 3mL dichloromethane, 1.5mL trifluoroacetic acids are added, stirring is anti-
Answer 1 hour.Reaction solution is concentrated under reduced pressure, with high performance liquid chromatography purify gained residue, obtain title product 8 (20mg, production
Rate:12%).
MS m/z(ESI):751.5[M+1]
1H NMR(400MHz,DMSO-d6)δ7.35-7.26(m,8H),7.22-7.18(m,2H),4.83(br,1H),
4.72(br,1H),4.41-4.36(m,2H),4.08-4.02(m,2H),3.76(br,1H),3.68(s,6H),3.60(br,
2H),3.27-3.22(m,6H),3.09(br,1H),3.01-2.98(m,2H),2.96-2.92(m,1H),2.73(d,3H),
1.98-1.92(m,2H),1.68-1.62(m,5H),1.46-1.42(m,7H),0.98(dd,6H).
Embodiment 9
(R) -2- ((R) -2- ((R) -2- amino -3- phenylpropionyls amino) -3- phenylpropionyls amino)-N- ((R) -6-
((2- methoxy ethyls) amino) -1- (4- (3- methyl urea groups) piperidin-1-yl) -1- oxohexane -2- bases) -4- methyl valeryls
Amine 9
The first step
(R)-(6- ((2- methoxy ethyls) amino) -1- (4- (3- methyl urea groups) piperidin-1-yl) -1- oxohexanes -2-
Base) benzyq carbamate 9b
Crude product 8c (330mg, 0.788mmol) is dissolved in 6mL DMFs, the bromo- 2- methoxyl groups of 1- are added
Ethane 9a (164mg, 1.182mmol) and potassium carbonate (230mg, 1.67mmol), are warming up to 90 DEG C of stirring reactions 5 hours.Reaction
Liquid is cooled to room temperature, adds 30mL ethyl acetate, is washed with saturated nacl aqueous solution (20mL × 3), anhydrous sodium sulfate drying, mistake
Filter, filtrate decompression concentration obtains crude title product 9b (376mg), and product is not purified directly to carry out next step reaction.
Second step
(R)-(5- (((benzyloxy) carbonyl) amino) -6- (4- (3- methyl urea groups) piperidin-1-yl) -6- oxo-hexyls)
(2- methoxy ethyls) t-butyl carbamate 9c
Crude product 9b (500mg, 0.75mmol) is dissolved in 15mL dichloromethane, di-tert-butyl dicarbonate is added
(330mg, 1.5mmol) and triethylamine (227mg, 2.25mmol), stirring reaction 2.5 hours.30mL dichloros are added in reaction solution
Methane, successively with saturated ammonium chloride solution (20mL × 3), saturated sodium bicarbonate solution (20mL × 3) and saturated nacl aqueous solution
(20mL × 3) are washed, anhydrous sodium sulfate drying, filtering, filtrate decompression concentration, are purified with thin-layered chromatography with solvent system A
Gained residue, obtains title product 9c (190mg, yield:44%).
3rd step
(R)-(5- amino -6- (4- (3- methyl urea groups) piperidin-1-yl) -6- oxo-hexyls) (2- methoxy ethyls) amino
T-butyl formate 9d
9c (160mg, 0.328mmol) is dissolved in 5mL methanol, palladium carbon (50mg, 10%) is added, hydrogen is replaced three times,
Stirring reaction 15 hours.Reacting liquid filtering, filtrate decompression concentration, obtains crude title product 9d (120mg), product is not purified
Directly carry out next step reaction.
4th step
((6R, 9R, 12R, 15R) -6,9- dibenzyl -12- isobutyl group -2,2- dimethyl -15- (4- (3- methyl urea groups) piperazines
Pyridine -1- carbonyls) four oxo -3- oxa-s -5,8,11,14- of -4,7,10,13-, four azepine nonadecane -19- bases) (2- methoxyl group second
Base) t-butyl carbamate 9e
By crude product 9d (120mg, 0.27mmol), 1h (145mg, 0.27mmol) is dissolved in 5mL DMFs
In, addition 2- (7- azo phenylpropyl alcohol triazole -1- bases)-N, N, N', N'- tetramethylurea hexafluorophosphoric acids ester (150mg,
0.405mmol) with DIPEA (104mg, 0.81mmol), stirring reaction 15 hours.50mL is added in reaction solution
Ethyl acetate, successively with saturated ammonium chloride solution (20mL × 3), saturated sodium bicarbonate solution (20mL × 3) and saturated sodium-chloride
Solution (20mL × 3) is washed, anhydrous sodium sulfate drying, filtering, filtrate decompression concentration, obtains crude title product 9e (250mg),
Product is not purified directly to carry out next step reaction.MS m/z(ESI):951.6[M+1]
5th step
(R) -2- ((R) -2- ((R) -2- amino -3- phenylpropionyls amino) -3- phenylpropionyls amino)-N- ((R) -6-
((2- methoxy ethyls) amino) -1- (4- (3- methyl urea groups) piperidin-1-yl) -1- oxohexane -2- bases) -4- methyl valeryls
Amine 9
Crude product 9e (250mg, 0.263mmol) is dissolved in 3mL dichloromethane, 1.5mL trifluoroacetic acids are added, stirring is anti-
Answer 1.5 hours.Reaction solution is concentrated under reduced pressure, with high performance liquid chromatography purify gained residue, obtain title product 9 (20mg, production
Rate:10%).
MS m/z(ESI):751.5[M+1]
1H NMR(400MHz,DMSO-d6)δ7.37-7.23(m,8H),7.21(br,1H),4.86-4.82(m,1H),
4.70-4.66(m,1H),4.39-4.36(m,2H),4.12-4.08(m,1H),3.75-3.72(m,6H),3.65-3.60(m,
4H),3.41(s,3H),3.20-3.15(m,4H),3.01-2.95(m,5H),2.94(d,3H),2.75-2.73(m,3H),
1.92-1.89(m,2H),1.67-1.62(m,7H),1.45-1.42(m,5H),0.98(dd,6H).
Embodiment 10
1- (((R) -5- ((R) -2- ((R) -2- ((R) -2- amino -3- phenylpropionyls amino) -3- phenylpropionyls amino) -
4- methylpentanoylaminos) -6- (4- (3- methyl urea groups) piperidin-1-yl) -6- oxo-hexyls) carbamoyl) piperidines -4- carboxylic acids
10
The first step
(R) -1- ((5- (((benzyloxy) carbonyl) amino) -6- (4- (3- methyl urea groups) piperidin-1-yl) -6- oxos oneself
Base) carbamoyl) piperidines -4- carboxylic acid, ethyl esters 10b
Crude product 8c (124mg, 0.273mmol) and triethylamine (95 μ L, 0.681mmol) are dissolved in 20mL dichloromethane,
Add 1- (chlorocarbonyl) piperidines -4- carboxylic acid, ethyl esters 10a (50mg, 0.227mmol, using patent application " CN102108092 " disclosure
Method be prepared), be warming up to 40 DEG C of stirring reactions 12 hours.Reaction solution is cooled to room temperature, is concentrated under reduced pressure, and uses thin-layer chromatography
Method purifies gained residue with solvent system A, obtains title product 10b (50mg, yield:36%).
Second step
(R) -1- ((5- amino -6- (4- (3- methyl urea groups) piperidin-1-yl) -6- oxo-hexyls) carbamoyl) piperazine
Pyridine -4- carboxylic acid, ethyl esters 10c
10b (50mg, 0.083mmol) is dissolved in 10mL methanol, palladium carbon (10mg, 10%) is added, hydrogen is replaced three times,
Stirring reaction 12 hours.Reacting liquid filtering, filtrate decompression concentration, obtains crude title product 10c (45mg), product is not purified
Directly carry out next step reaction.
3rd step
1- (((6R, 9R, 12R, 15R) -6,9- dibenzyl -12- isobutyl group -2,2- dimethyl -15- (4- (3- MUs
Base) piperidines -1- carbonyls)) four oxo -3- oxa-s -5,8,11,14- of -4,7,10,13-, four azepine nonadecane -19- bases) amino first
Acyl group) piperidines -4- carboxylic acid, ethyl esters 10d
By crude product 10c (45mg, 0.083mmol), 1h (43.6mg, 0.083mmol) is dissolved in 3mL N, N- dimethyl methyls
In acid amides, addition 2- (7- azo phenylpropyl alcohol triazole -1- bases)-N, N, N', N'- tetramethylurea hexafluorophosphoric acids ester (47mg,
0.124mmol) with triethylamine (23 μ L, 0.166mmol), stirring reaction 3 hours.Reaction solution is concentrated under reduced pressure, and uses thin-layered chromatography
Gained residue is purified with solvent system A, title product 10d (40mg, yield is obtained:51%).
4th step
1- (((6R, 9R, 12R, 15R) -6,9- dibenzyl -12- isobutyl group -2,2- dimethyl -15- (4- (3- MUs
Base) piperidines -1- carbonyls)) four oxo -3- oxa-s -5,8,11,14- of -4,7,10,13-, four azepine nonadecane -19- bases) amino first
Acyl group) piperidines -4- carboxylic acids 10e
10d (40mg, 0.041mmol) is dissolved in 9mL tetrahydrofurans, first alcohol and water (V/V/V=4:4:1) mixed solvent
In, add a hydronium(ion) lithia (3.4mg, 0.082mmol), stirring reaction 1 hour.1M hydrochloric acid is added dropwise into reaction solution to pH
For 2, it is concentrated under reduced pressure, obtains crude title product 10e (40mg), product is not purified directly carries out next step reaction.
MS m/z(ESI):948.6[M+1]
5th step
1- (((R) -5- ((R) -2- ((R) -2- ((R) -2- amino -3- phenylpropionyls amino) -3- phenylpropionyls amino) -
4- methylpentanoylaminos) -6- (4- (3- methyl urea groups) piperidin-1-yl) -6- oxo-hexyls) carbamoyl) piperidines -4- carboxylic acids
Trifluoroacetate 10f
Crude product 10e (40mg, 0.041mmol) is dissolved in 5mL dichloromethane, 1mL trifluoroacetic acids, stirring reaction 2 is added
Hour.Reaction solution is concentrated under reduced pressure, with high performance liquid chromatography purify gained residue, obtain title product 10f (5mg, yield:
13%).
MS m/z(ESI):849.1[M+1]
1H NMR(400MHz,DMSO-d6):δ10.61(s,1H),8.39(d,2H),8.16(t,3H),7.21-7.41(m,
13H),4.86(d,1H),4.73(d,1H),4.46(d,1H),4.05-4.11(m,1H),3.90-4.05(m,4H),3.70-
3.80(m,2H),3.15-3.31(m,4H),2.83-3.03(m,5H),2.71(s,3H),2.49-2.52(m,1H),1.84-
2.08(m,4H),1.49-1.82(m,8H),1.24-1.47(m,5H),1.00(d,3H),0.96(d,3H).
6th step
1- (((R) -5- ((R) -2- ((R) -2- ((R) -2- amino -3- phenylpropionyls amino) -3- phenylpropionyls amino) -
4- methylpentanoylaminos) -6- (4- (3- methyl urea groups) piperidin-1-yl) -6- oxo-hexyls) carbamoyl) piperidines -4- carboxylic acids
10
10f (5mg, 0.005mmol) is dissolved in 1mL dichloromethane and methanol (V:V=10:1) mixed solution dissolved clarification,
Saturated aqueous sodium carbonate regulation pH to 7 or so is added dropwise, stirring reaction 30 minutes, static layering, collect organic phase, nothing at room temperature
Water magnesium sulfate is dried, filtering, filtrate decompression concentration, obtains title product 10 (4.4mg, yield:100%).
MS m/z(ESI):849.1[M+1]
Embodiment 11
(R) -2- ((R) -2- ((R) -2- amino -3- phenylpropionyls amino) -3- phenylpropionyls amino) -4- methyl-N-
((R) -6- (3- methyl urea groups) -1- (4- (3- methyl urea groups) piperidin-1-yl) -1- oxohexane -2- bases) pentanamide 11
The first step
(R)-(6- amino -1- (4- (3- methyl urea groups) piperidin-1-yl) -1- oxohexane -2- bases) benzyq carbamate
11a
Crude product 8b (390mg, 0.751mmol) is dissolved in 5mL dichloromethane, 1mL trifluoroacetic acids, stirring reaction 1 is added
Hour.Reaction solution is concentrated under reduced pressure, and obtains crude title product 11a (310mg), and the not purified directly progress next step of product is anti-
Should.
Second step
(6- (3- methyl urea groups) -1- (4- (3- methyl urea groups) piperidin-1-yl) -1- oxohexane -2- bases) carbamic acid
Benzyl ester 11b
Crude product 11a (310mg, 0.739mmol) and triethylamine (224mg, 2.218mmol) are dissolved in 5mL dichloromethane,
0 DEG C is cooled to, methyl amido formyl chloride (83mg, 0.888mmol), stirring reaction 2 hours is added.Reaction solution is concentrated under reduced pressure, and uses
Silica gel column chromatography purifies gained residue with solvent system A, obtains title product 11b (230mg, yield:66%).
3rd step
1- { 1- [(2R) -2- amino -6- [(methylcarbamoyl) amino] caproyl] piperidin-4-yl } -3- MUs
11c
11b (230mg, 0.483mmol) is dissolved in 5mL methanol, palladium carbon (23mg, 10%) is added, hydrogen is replaced three times,
Stirring reaction 12 hours.Reacting liquid filtering, filtrate decompression concentration, obtains crude title product 11c (160mg), product is without pure
Change and directly carry out next step reaction.
4th step
((9R, 12R, 15R, 18R) -15- benzyl -12- isobutyl groups -9- (4- (3- methyl urea groups) piperidines -1- carbonyls)) -3,
Oxo -19- phenyl -2,4,10,13,16- pentaaza nonadecane -18- the bases of 11,14,17- tetra-) t-butyl carbamate 11d
By crude product 11c (160mg, 0.467mmol), 1h (250mg, 0.476mmol) is dissolved in 3mL N, N- dimethyl methyls
In acid amides, addition 2- (7- azo phenylpropyl alcohol triazole -1- bases)-N, N, N', N'- tetramethylurea hexafluorophosphoric acids ester (266mg,
0.7mmol) with DIPEA (180mg, 1.393mmol), stirring reaction 12 hours.Reaction solution is concentrated under reduced pressure, institute
Residue in add 30mL ethyl acetate, filtering, collect filter cake, dry, obtain crude title product 11d (155mg), product
It is not purified directly to carry out next step reaction.
MS m/z(ESI):850.7[M+1]
5th step
(R) -2- ((R) -2- ((R) -2- amino -3- phenylpropionyls amino) -3- phenylpropionyls amino) -4- methyl-N-
((R) -6- (3- methyl urea groups) -1- (4- (3- methyl urea groups) piperidin-1-yl) -1- oxohexane -2- bases) pentanamide trifluoro second
Hydrochlorate 11e
Crude product 11d (150mg, 0.176mmol) is dissolved in 7.5mL dichloromethane, 1.5mL trifluoroacetic acids is added, stirs
Mix reaction 1 hour.Reaction solution is concentrated under reduced pressure, with high performance liquid chromatography purify gained residue, obtain title product 11e
(90mg, yield:69%).
MS m/z(ESI):750.3[M+1]
1H NMR(400MHz,DMSO-d6):δ8.45(d,2H),8.23(t,3H),7.22-7.40(m,14H),4.85-
4.87(m,1H),4.74-4.77(m,1H),4.31-4.42(m,2H),4.09-4.11(m,1H),3.98(t,1H),3.67-
3.73(m,1H),3.20-3.34(m,2H),3.05-3.16(m,2H),2.85-3.01(m,3H),2.71(s,3H),2.70(s,
3H),1.87-2.05(m,2H),1.25-1.83(m,12H),1.00(d,3H),0.96(d,3H).
6th step
(R) -2- ((R) -2- ((R) -2- amino -3- phenylpropionyls amino) -3- phenylpropionyls amino) -4- methyl-N-
((R) -6- (3- methyl urea groups) -1- (4- (3- methyl urea groups) piperidin-1-yl) -1- oxohexane -2- bases) pentanamide 11
11e (90mg, 0.104mmol) is dissolved in 5mL dichloromethane and methanol (V:V=10:1) mixed solution is molten
Clearly, saturated aqueous sodium carbonate regulation pH to 7 or so is added dropwise, stirring reaction 30 minutes, static layering, are collected organic at room temperature
Phase, anhydrous magnesium sulfate is dried, filtering, filtrate decompression concentration, obtains title product 11 (78mg, yield:100%).
MS m/z(ESI):750.3[M+1]
Embodiment 12
(R) -2- ((R) -2- ((R) -2- amino -3- phenylpropionyls amino) -3- phenylpropionyls amino) -4- methyl-N-
((R) -1- (4- (3- methyl urea groups) piperidin-1-yl) -1- oxo -6- urea groups hexane -2- bases) pentanamide 12
The first step
(R)-(1- (4- (3- methyl urea groups) piperidin-1-yl) -1- oxo -6- urea groups hexane -2- bases) benzyq carbamate
12b
Crude product 8c (200mg, 0.44mmol) is dissolved in 10mL dichloromethane, trimethyl silicane based isocyanate 12a is added
(202mg, 1.76mmol) and triethylamine (178mg, 1.76mmol), stirring reaction 12 hours.Reaction solution is concentrated under reduced pressure, and obtains thick
Product title product 12b (203mg), product is not purified directly to carry out next step reaction.
Second step
(R) -1- (1- (2- amino -- 6- urea groups caproyl) piperidin-4-yl) -3- MUs 12c
Crude product 12b (140mg, 0.303mmol) is dissolved in 5mL methanol, palladium carbon (40mg, 10%), hydrogen displacement is added
Three times, stirring reaction 1 hour.Reacting liquid filtering, filtrate decompression concentration, obtains crude title product 12c (99mg), product without
Purifying directly carries out next step reaction.
3rd step
((7R, 10R, 13R, 16R) -1- amino -13- benzyl -10- isobutyl groups -7- (4- (3- methyl urea groups) piperidines -1- carbonyls
Base) four oxo -17- phenyl -2,8,11,14- of -1,9,12,15-, four azepine heptadecane -16- bases) t-butyl carbamate 12d
By crude product 12c (100mg, 0.3mmol), 1h (160mg, 0.31mmol) is dissolved in 3mL DMFs
In, add 2- (7- azo phenylpropyl alcohol triazole -1- bases)-N, N, N', N'- tetramethylurea hexafluorophosphoric acid esters (170mg, 0.45mmol)
With triethylamine (60mg, 0.6mmol), stirring reaction 12 hours.Reaction solution is concentrated under reduced pressure, with thin-layered chromatography with solvent system
A purifying gained residues, obtain title product 12d (200mg, yield:80%).
MS m/z(ESI):836.4[M+1]
4th step
(R) -2- ((R) -2- ((R) -2- amino -3- phenylpropionyls amino) -3- phenylpropionyls amino) -4- methyl-N-
((R) -1- (4- (3- methyl urea groups) piperidin-1-yl) -1- oxo -6- urea groups hexane -2- bases) pentanamide trifluoroacetate 12e
12d (200mg, 0.24mmol) is dissolved in 5mL dichloromethane, 3mL trifluoroacetic acids, stirring reaction 1 hour is added.
Reaction solution is concentrated under reduced pressure, with high performance liquid chromatography purify gained residue, obtain title product 12e (20mg, yield:
11%).
MS m/z(ESI):736.2[M+1]
1H NMR(400MHz,DMSO-d6)δ8.46(br,3H),7.42-7.23(m,10H),6.01(br,5H),5.10
(br,2H),4.74-4.73(m,1H),4.35-4.31(m,2H),4.01-3.99(m,2H),3.80-3.76(m,1H),3.28-
2.92(m,8H),2.70(s,3H),2.20-1.78(m,14H),0.98-0.96(m,6H).
5th step
(R) -2- ((R) -2- ((R) -2- amino -3- phenylpropionyls amino) -3- phenylpropionyls amino) -4- methyl-N-
((R) -1- (4- (3- methyl urea groups) piperidin-1-yl) -1- oxo -6- urea groups hexane -2- bases) pentanamide 12
12e (20mg, 0.024mmol) is dissolved in 2mL dichloromethane and methanol (V:V=10:1) mixed solution is molten
Clearly, saturated aqueous sodium carbonate regulation pH to 7 or so is added dropwise, stirring reaction 30 minutes, static layering, are collected organic at room temperature
Phase, anhydrous magnesium sulfate is dried, filtering, filtrate decompression concentration, obtains title product 12 (17mg, yield:98%).
MS m/z(ESI):736.2[M+1]
Embodiment 13
(8R, 11R, 14R, 17R) -17- amino -14- benzyl -11- isobutyl groups -8- (4- (3- methyl urea groups) piperidines -1- carbonyls
Base) four azepines of-10,13,16- trioxy--18- phenyl-3,9,12,15-, 18-1- acid 13
The first step
(R) -2- ((5- (((benzyloxy) carbonyl) amino) -6- (4- (3- methyl urea groups) piperidin-1-yl) -6- oxos oneself
Base) amino) methyl acetate 13b
Crude product 11a (640mg, 1.4mmol) is dissolved in 10mL DMFs, 2- methyl chloroacetates are added
13a (122mg, 1.12mmol), KI (465mg, 2.8mmol) and potassium carbonate (773mg, 5.6mmol), are warming up to 60 DEG C and stir
Mix reaction 1.5 hours.Reaction solution is cooled to room temperature, adds water, is extracted with ethyl acetate (20mL × 3), merges organic phase, with full
With sodium chloride solution (20mL × 3) washing, anhydrous sodium sulfate drying, filtering, filtrate decompression concentration obtains crude title product
13b (700mg), product is not purified directly to carry out next step reaction.
Second step
(R) -2- ((5- (((benzyloxy) carbonyl) amino) -6- (4- (3- methyl urea groups) piperidin-1-yl) -6- oxos oneself
Base) (tertbutyloxycarbonyl) amino) methyl acetate 13c
Crude product 13b (700mg, 1.4mmol) is dissolved in 20mL dichloromethane, di-tert-butyl dicarbonate is added
(466mg, 2.1mmol) and triethylamine (283mg, 2.8mmol), stirring reaction 12 hours.Reaction solution is concentrated under reduced pressure, and uses thin layer color
Spectrometry purifies gained residue with solvent system A, obtains title product 13c (200mg, yield:24%).
3rd step
(R) -2- ((5- amino -6- (4- (3- methyl urea groups) piperidin-1-yl) -6- oxo-hexyls) (tertbutyloxycarbonyl) ammonia
Base) methyl acetate 13d
13c (200mg, 0.34mmol) is dissolved in 10mL methanol, palladium carbon (20mg, 10%) is added, hydrogen is replaced three times,
Stirring reaction 12 hours.Reacting liquid filtering, filtrate decompression concentration, obtains crude title product 13d (150mg), product is without pure
Change and directly carry out next step reaction.
4th step
(6R, 9R, 12R, 15R) -6,9- dibenzyl -20- (tertbutyloxycarbonyl) -12- isobutyl group -2,2- dimethyl -15-
Oxo -3- oxa- -5,8,11,14,20- the pentaazas 20 of (4- (3- methyl urea groups) piperidines -1- carbonyls) -4,7,10,13- four
Two -22- acid methyl esters 13e
By crude product 13d (150mg, 0.33mmol), 1h (172mg, 0.33mmol) is dissolved in 10mL N, N- dimethyl formyls
In amine, addition 2- (7- azo phenylpropyl alcohol triazole -1- bases)-N, N, N', N'- tetramethylurea hexafluorophosphoric acids ester (188mg,
0.5mmol) with DIPEA (85mg, 0.66mmol), stirring reaction 12 hours.Reaction solution is concentrated under reduced pressure, with thin
Layer chromatography purifies gained residue with solvent system A, obtains title product 13e (120mg, yield:38%).
5th step
(6R, 9R, 12R, 15R) -6,9- dibenzyl -20- (tertbutyloxycarbonyl) -12- isobutyl group -2,2- dimethyl -15-
Oxo -3- oxa- -5,8,11,14,20- the pentaazas 20 of (4- (3- methyl urea groups) piperidines -1- carbonyls) -4,7,10,13- four
Two -22- acid 13f
13e (80mg, 0.082mmol) is dissolved in 10mL tetrahydrofurans and water (V/V=5:1) in the mixed solvent, is added
One hydronium(ion) lithia (14mg, 0.33mmol), stirring reaction 12 hours.It is 6 that 2M hydrochloric acid is added dropwise into reaction solution to pH, uses second
Acetoacetic ester extracts (20mL × 3), merges organic phase, is washed with saturated nacl aqueous solution (20mL × 3), anhydrous sodium sulfate drying,
Filtering, filtrate decompression concentration obtains crude title product 13f (70mg), and product is not purified directly to carry out next step reaction.
MS m/z(ESI):951.6[M+1]
6th step
(8R, 11R, 14R, 17R) -17- amino -14- benzyl -11- isobutyl groups -8- (4- (3- methyl urea groups) piperidines -1- carbonyls
Base) four azepines of-10,13,16- trioxy--18- phenyl-3,9,12,15-, 18-1- acid 13
Crude product 13f (70mg, 0.0736mmol) is dissolved in 1mL dichloromethane, 1mL trifluoroacetic acids are added, stirring is anti-
Answer 2 hours.Reaction solution is concentrated under reduced pressure, with high performance liquid chromatography purify gained residue, obtain title product 13 (50mg, production
Rate:91%).
MS m/z(ESI):751.7[M+1]
1H NMR(400MHz,DMSO-d6)δ7.40-7.23(m,10H),4.74-4.75(m,1H),4.37-4.35(m,
1H),4.17-4.12(m,6H),3.85-3.82(m,1H),3.77-3.76(m,2H),3.74-3.69(m,4H),3.68-3.66
(m,1H),3.28-3.22(m,6H),3.20-3.03(m,4H),2.70(s,3H),1.75-1.70(m,6H),1.47-1.30
(m,7H),0.98-0.96(m,6H).
Embodiment 14
(R)-N- ((R) -6- amino -1- (4- (3- ethyls urea groups) piperidin-1-yl) -1- oxohexane -2- bases) -2-
((R) -2- ((R) -2- amino -3- phenylpropionyls amino) -3- phenylpropionyls amino) -4- methylpentanamides 14
The first step
4- (3- ethyls urea groups) piperidines -1- t-butyl formates 14a
Crude product 1b (0.15g, 0.469mmol) is dissolved in 10mL methanol, addition ethylamine hydrochloride (38mg,
0.469mmol) and sodium carbonate (50mg, 0.469mmol), 50 DEG C of stirring reactions are warming up to 12 hours.Reaction solution is cooled to room temperature,
It is concentrated under reduced pressure, with dichloromethane and methanol (V/V=10:1) mixed solvent mashing, filtering is collected filter cake, dried, and obtains thick
Product title product 14a (0.18g), product is not purified directly to carry out next step reaction.
Second step
1- ethyls -3- (piperidin-4-yl) urea trifluoroacetate 14b
Crude product 14a (0.18g, 0.469mmol) is dissolved in 5mL dichloromethane, 1mL trifluoroacetic acids are added, stirring is anti-
Answer 2 hours.Reaction solution is concentrated under reduced pressure, and obtains crude title product 14b (0.15g), the not purified direct carry out next step of product
Reaction.
3rd step
(R)-(9H- fluorenes -9- bases) methyl tertbutyl (6- (4- (3- ethyls urea groups) piperidin-1-yl) -6- oxohexane -1,
5- diyls) diurethane 14c
By crude product 14b (0.15g, 0.469mmol), 1e (220mg, 0.469mmol) is dissolved in 5mL N, N- dimethyl methyls
In acid amides, addition 2- (7- azo phenylpropyl alcohol triazole -1- bases)-N, N, N', N'- tetramethylurea hexafluorophosphoric acids ester (0.267g,
0.704mmol) with triethylamine (0.23mL, 0.938mmol), stirring reaction 2 hours.Reaction solution is concentrated under reduced pressure, and uses thin-layer chromatography
Method purifies gained residue with solvent system A, obtains title product 14c (360mg, yield:100%).
4th step
(R)-(5- amino -6- (4- (3- ethyls urea groups) piperidin-1-yl) -6- oxo-hexyls) t-butyl carbamate 14d
14c (360mg, 0.469mmol) is dissolved in 5mL dichloromethane, 2mL hexahydropyridines are added, stirring reaction 2 is small
When.Reaction solution is concentrated under reduced pressure, and adds water, is extracted with ethyl acetate, organic phase anhydrous sodium sulfate drying, filters, filtrate decompression
Concentration, obtains crude title product 14d (200mg), and product is not purified directly to carry out next step reaction.
5th step
N- [(5R) -5- [(2R) -2- [(2R) -2- [(2R) -2- { [(tert-butoxy) carbonyl] amino } -3- phenylpropionyl ammonia
Base] -3- phenylpropionyls amino] -4- methylpentanoylaminos] -6- { 4- [(ethylaminocarbonyl) amino] piperidin-1-yl } -6-
Oxo-hexyl] t-butyl carbamate 14e
By crude product 14d (200mg, 0.469mmol), 1h (246mg, 0.469mmol), 2- (7- azo phenylpropyl alcohol triazoles -1-
Base)-N, N, N', N'- tetramethylurea hexafluorophosphoric acid esters (267mg, 0.703mmol) and triethylamine (0.13mL, 0.938mmol) are molten
Solution is in 5mL DMFs, stirring reaction 12 hours.Reaction solution is concentrated under reduced pressure, with thin-layered chromatography with solvent
System A purifying gained residues, obtain title product 14e (120mg, yield:28%).
MS m/z(ESI):907.6[M+1]
6th step
(R)-N- ((R) -6- amino -1- (4- (3- ethyls urea groups) piperidin-1-yl) -1- oxohexane -2- bases) -2-
((R) -2- ((R) -2- amino -3- phenylpropionyls amino) -3- phenylpropionyls amino) -4- methylpentanamides 14
14e (120mg, 0.132mmol) is dissolved in 5mL dichloromethane, 1mL trifluoroacetic acids are added, stirring reaction 2 is small
When.Reaction solution is concentrated under reduced pressure, with high performance liquid chromatography purify gained residue, obtain title product 14 (30mg, yield:
14%).
MS m/z(ESI):707.2[M+1]
1H NMR(400MHz,DMSO-d6):δ8.44(d,2H),8.22(t,3H),7.21-7.41(m,12H),4.75(d,
1H),4.41(d,2H),4.06-4.11(m,1H),3.74(s,1H),3.20-3.30(m,3H),3.10-3.19(m,3H),
2.90-3.03(m,6H),1.84-2.06(m,2H),1.56-1.85(m,7H),1.30-1.55(m,6H),1.10(t,3H),
1.01(d,3H),0.97(d,3H).
Embodiment 15
(R)-N- ((R) -6- amino -1- (4- (3- cyclopropylureidos) piperidin-1-yl) -1- oxohexane -2- bases) -2-
((R) -2- ((R) -2- amino -3- phenylpropionyls amino) -3- phenylpropionyls amino) -4- methylpentanamides 15
The first step
(R)-(9H- fluorenes -9- bases) methyl tertbutyl (6- (4- (3- cyclopropylureidos) piperidin-1-yl) -6- oxohexanes -
1,5- diyls) diurethane 15b
By 1- cyclopropyl -3- (piperidin-4-yl) ureas 15a (0.2g, 1mmol, using patent application " WO2016035814 " public affairs
The method opened is prepared), 1e (500mg, 1mmol) is dissolved in 5mL DMFs, adds 2- (7- azobenzenes
Third triazole -1- bases)-N, N, N', N'- tetramethylurea hexafluorophosphoric acid esters (0.57g, 1.5mmol) and triethylamine (202mg,
2mmol), stirring reaction 48 hours.Reaction solution is concentrated under reduced pressure, with thin-layered chromatography with solvent system A purify gained residue,
Obtain title product 15b (200mg, yield:100%).
Second step
(R)-(5- amino -6- (4- (3- cyclopropylureidos) piperidin-1-yl) -6- oxo-hexyls) t-butyl carbamate
15c
15b (700mg, 1.11mmol) is dissolved in 3mL dichloromethane, 3mL hexahydropyridines, stirring reaction 0.5 is added
Hour.Reaction solution is concentrated under reduced pressure, and obtains crude title product 15c (455mg), and the not purified directly progress next step of product is anti-
Should.
3rd step
N- [(5R) -5- [(2R) -2- [(2R) -2- [(2R) -2- { [(tert-butoxy) carbonyl] amino } -3- phenylpropionyl ammonia
Base] -3- phenylpropionyls amino] -4- methylpentanoylaminos] -6- { 4- [(cyclopropylcarbamoyl) amino] piperidin-1-yl } -
6- oxo-hexyls] t-butyl carbamate 15d
By crude product 15c (411.28mg, 1mmol), 1h (525.64mg, 1mmol), 2- (7- azo phenylpropyl alcohol triazoles -1-
Base)-N, N, N', N'- tetramethylurea hexafluorophosphoric acid esters (570mg, 1.5mmol) and triethylamine (218mg, 2mmol) are dissolved in 5mL
In DMF, stirring reaction 12 hours.Reaction solution is concentrated under reduced pressure, pure with solvent system A with thin-layered chromatography
Change gained residue, obtain title product 15d (300mg, yield:32.7%).
MS m/z(ESI):919.5[M+1]
4th step
(R)-N- ((R) -6- amino -1- (4- (3- cyclopropylureidos) piperidin-1-yl) -1- oxohexane -2- bases) -2-
((R) -2- ((R) -2- amino -3- phenylpropionyls amino) -3- phenylpropionyls amino) -4- methylpentanamide trifluoroacetates 15e
15d (300mg, 0.33mmol) is dissolved in 6mL dichloromethane, 2mL trifluoroacetic acids are added, stirring reaction 2 is small
When.Reaction solution is concentrated under reduced pressure, with high performance liquid chromatography purify gained residue, obtain title product 15e (40mg, yield:
17%).
MS m/z(ESI):719.2[M+1]
1H NMR(400MHz,DMSO-d6)δ8.46(br,3H),8.19(br,2H),7.42-7.23(m,10H),5.09
(br,4H),4.38-4.27(m,2H),4.19-4.16(m,2H),4.01-3.99(m,2H),3.80-3.76(m,1H),3.28-
2.92(m,8H),2.76-2.71(m,1H),2.20-1.78(m,13H),0.98-0.96(m,6H),0.82-0.57(m,4H).
5th step
(R)-N- ((R) -6- amino -1- (4- (3- cyclopropylureidos) piperidin-1-yl) -1- oxohexane -2- bases) -2-
((R) -2- ((R) -2- amino -3- phenylpropionyls amino) -3- phenylpropionyls amino) -4- methylpentanamides 15e
15e (40mg, 0.042mmol) is dissolved in 2mL dichloromethane and methanol (V:V=10:1) mixed solution is molten
Clearly, saturated aqueous sodium carbonate regulation pH to 7 or so is added dropwise, stirring reaction 30 minutes, static layering, are collected organic at room temperature
Phase, anhydrous magnesium sulfate is dried, filtering, filtrate decompression concentration, obtains title product 15 (30mg, yield:99%).
MS m/z(ESI):719.2[M+1]
Biological assessment
The explanation present invention is further described below in conjunction with test case, but these embodiments are not meant as the limitation present invention's
Scope.
Test case 1
1st, experiment purpose
The purpose of this experiment is the agonism in order to test the compounds of this invention to KOR acceptors, according to EC50Size is evaluated
The external activity of compound.
2nd, the test of KOR activity
2.1 experiment purpose
The compound of the present invention can activate KOR acceptors (KOR), so as to reduce intracellular cAMP level;Second messenger
CAMP is combined into nucleus with DNA CRE, can start downstream luciferase (Luciferase) expression, luciferase
Fluorescence can be sent with its substrate reactions, the agonist activity of compound is reflected by determining fluorescence signal.
2.2 experimental method
The activity of embodiment compound excitement KOR influence downstream cAMP levels changes is tested by following method.
2.2.1 experiment material and instrument
1) laboratory apparatus
Instrument title | Supply of material company | Model |
ELIASA | PE | Vector3 |
96 hole round bottom plates | costar | 3795 |
White 96 hole flat undersides, clear bottom | Corning | 3903 |
2) experiment material
2.2.2 experimental procedure
1) acquisition of HEK293/KOR/CRE monoclonal cell strains
KOR/pcDNA3.1 (+) and CRE/pGL4.29 are transferred to HEK293 cell lines, by adding G418 in the medium
With hygromycin (Hygromycin), and HEK293/KOR/CRE monoclonal cell strains are filtered out in 96 porocyte culture plates.
2) embodiment compound is tested to KOR agonisms
HEK293/KOR/CRE monoclonal cell strains DMEM/ high glucoses culture medium (10%FBS, 1mg/ml G418,
200ug/ml hygromycin, is mixed) middle culture, passage in every 3 days is once.Experimental day is produced cell with Fresh cell culture medium and hanged
Liquid, 20,000 cells/wells spread 96 orifice plates (BD, #356692), the culture of 5% 37 DEG C of carbon dioxide.It is second day, first that compound is molten
Solution concentration in pure DMSO is 20mM, then is configured to DMSO first concentration 200nM, and is diluted to 8 concentration successively with 3 times,
The hole for being arranged to blank and control adds 90 μ l DMSO;With the DMEM/ high glucoses containing 10 μM of Forskolin
(SH30243.01B, Hyclone) culture medium dilutes 20 times.The Tissue Culture Plate of inoculation in first day is taken out, 10 are separately added into per hole
Medicine or control (0.5%DMSO) after μ l dilutions, gently vibration are mixed, and are placed 37 DEG C and are cultivated 4 hours.In 96 porocyte culture plates
In, 100 μ l luciferases detection liquid (Promega, #E6110) is added per hole, room temperature is placed 5 minutes, using Victor3.0's
Cold light pattern surveys absorption value.Compound is calculated with corresponding signal value according to each concentration of compound with Graphpad Prism softwares
EC50Value.Emax is the ceiling effect that compound causes cAMP levels to change.
2.3 test result
The change of the compound excitement KOR influence downstream cAMP levels of the present invention is measured by the experiment of the above, is surveyed
The EC obtained50Value is shown in Table 1.1.
The EC of the compounds of this invention of table 1.1 excitement KOR receptor influences cAMP levels50
Embodiment is numbered | EC50(pM) |
1 | 0.5 |
2 | 4. |
3 | 1 |
4 | 9 |
6 | 1 |
7 | 0.7 |
8 | 0.2 |
9 | 4 |
11 | 2 |
12 | 3 |
13 | 1 |
14 | 3 |
15 | 1 |
Conclusion:The compounds of this invention has obvious agonism to KOR acceptors.
Pharmacokinetic Evaluation
The pharmacokinetics test of test case 2, compound of the embodiment of the present invention
1st, make a summary
Using SD rats as animal subject, determine SD rat intravenous injections using LC/MS/MS methods and give embodiment 1 and real
Apply after the compound of example 7 drug concentration not in the same time in blood plasma.Medicine of the compounds of this invention in SD rat bodies is studied for power
Scholarship and moral conduct is to evaluate its characteristics of pharmacokinetics.
2nd, testing program
2.1 test drug
Embodiment 1 and the compound of embodiment 7
2.2 experimental animal
SD rats 8, male and female half and half are divided into 2 groups, purchased from the western pul-Bi Kai experimental animals Co., Ltd in Shanghai, animal life
Produce credit number:SCXK (Shanghai) 2008-0016.
2.3 medicines are prepared
Appropriate amount of sample is weighed, 5%DMSO+5%PEG400+90% physiological saline is added, sequentially adds in order.
2.4 administration
SD rats 8, male and female half and half are divided into 2 groups;Intravenous injection administration respectively, is administered 1mg/kg after the night of fasting one.
3rd, operate
Vein group 5min before being administered and after administration, 0.25,0.5,1.0,2.0,4.0,8.0,11.0,24.0h is by eye socket
Take a blood sample 0.2ml, is placed in heparinised tubes, 3500rpm centrifugation 10min separated plasmas, in -20 DEG C of preservations.
The testing compound content after different compound intravenous injection administrations in SD rat plasmas is determined with LC/MS/MS methods.
4th, SD pharmacokinetics in rats parametric results
The pharmacokinetic parameter of compound of the embodiment of the present invention is as follows:
Conclusion:The medicine of the compounds of this invention is for well-behaved.
Claims (16)
1. the compound shown in a kind of logical formula (I):
Or its dynamic isomer, mesomer, racemic modification, enantiomter, diastereoisomer or its form of mixtures, or
Its pharmaceutically useful salt,
Wherein:
G is C=O or O=S=O;
R1Selected from hydrogen atom, alkyl, alkoxy, haloalkyl, halogen, amino, nitro, hydroxyl, cyano group, cycloalkyl, heterocyclic radical,
Aryl, heteroaryl ,-OR3、-C(O)R3、-C(O)OR3、-S(O)mR3With-NR4R5, wherein described alkyl, haloalkyl, cycloalkanes
Base, heterocyclic radical, aryl and heteroaryl are optionally selected from alkyl, haloalkyl, halogen, amino, nitro, cyano group, hydroxyl, alcoxyl
Base, halogenated alkoxy, hydroxyalkyl, cycloalkyl, heterocyclic radical, aryl, heteroaryl and NR6R7One or more of substituent taken
Generation;
R2Selected from hydrogen atom, alkyl, alkoxy, haloalkyl, cycloalkyl, heterocyclic radical, aryl, heteroaryl ,-OR3、-C(O)R3
With-C (O) OR3, wherein described alkyl, haloalkyl, cycloalkyl, heterocyclic radical, aryl and heteroaryl be optionally selected from alkyl,
Haloalkyl, halogen, amino, nitro, cyano group, hydroxyl, alkoxy, halogenated alkoxy, hydroxyalkyl, cycloalkyl, heterocyclic radical, aryl
Replaced with one or more of heteroaryl substituent;
R3Selected from hydrogen atom, alkyl, amino, alkoxy, hydroxyalkyl, cycloalkyl, heterocyclic radical, aryl and heteroaryl, wherein described
Alkyl, cycloalkyl, heterocyclic radical, aryl and heteroaryl are optionally selected from alkyl, halogen, hydroxyl, amino, nitro, cyano group, alcoxyl
One or more of base, hydroxyalkyl, cycloalkyl, heterocyclic radical, aryl and heteroaryl substituent is replaced;
R4And R5Be each independently selected from hydrogen atom, it is alkyl, alkoxy, hydroxyalkyl, hydroxyl, amino, carboxylic acid ester groups, cycloalkyl, miscellaneous
Ring group, aryl and heteroaryl, wherein described alkyl, cycloalkyl, heterocyclic radical, aryl and heteroaryl are optionally selected from alkyl, halogen
In element, hydroxyl, amino, carboxylic acid ester groups, nitro, cyano group, alkoxy, hydroxyalkyl, cycloalkyl, heterocyclic radical, aryl and heteroaryl
One or more substituents are replaced;
R6For hydrogen atom or W;
R7Selected from hydrogen atom, alkyl, C (O) R8、C(O)OR8、C(O)NR9R10Or W, wherein described alkyl is optionally selected from alcoxyl
One or more of base, hydroxyalkyl, cycloalkyl, heterocyclic radical, carboxylic acid group and carboxylic acid ester groups substituent is replaced;
R8Selected from hydrogen atom, alkyl, alkoxy, amino, cycloalkyl and heterocyclic radical, wherein described heterocyclic radical is optionally selected from alkane
One or more of base, alkoxy, hydroxyalkyl, cycloalkyl, heterocyclic radical, carboxylic acid group and carboxylic acid ester groups substituent is replaced;
R9And R10It is each independently selected from hydrogen atom, alkyl or haloalkyl;Wherein described alkyl be optionally selected from carboxylic acid group,
One or more of alkoxy, amino, cyano group, nitro, hydroxyl, hydroxyalkyl, cycloalkyl, heterocyclic radical, aryl and heteroaryl take
Replaced for base;
Or, R9And R10Heterocyclic radical is formed together with the nitrogen-atoms being connected, wherein containing 1~2 phase in described heterocyclic radical
The same or different hetero atoms for being selected from N, O and S, and described heterocyclic radical is optionally selected from alkyl, alkoxy, halogen, amino, cyanogen
One or more of base, nitro, hydroxyl, hydroxyalkyl, cycloalkyl, heterocyclic radical, carboxylic acid group, carboxylic acid ester groups, aryl and heteroaryl
Substituent is replaced;
W is amino protecting group;And
M is 0,1 or 2.
2. the compound shown in logical formula (I) according to claim 1, it is the compound shown in logical formula (II):
Or its dynamic isomer, mesomer, racemic modification, enantiomter, diastereoisomer or its form of mixtures, or
Its officinal salt,
Wherein:
R1And R2As defined in claim 1.
3. the compound or its salt according to logical formula (I) according to any one of claims 1 to 2, wherein R1For alkyl or
OR3, wherein described alkyl is optionally by NR6R7Substituent is replaced;
R3Selected from alkyl or heterocyclic radical, wherein described alkyl is optionally selected from cycloalkyl, heterocyclic radical, aryl and heteroaryl
One or more substituents are replaced;
R6For hydrogen atom;
R7Selected from hydrogen atom, alkyl, C (O) OR8Or C (O) NR9R10, wherein described alkyl is optionally selected from alkoxy, hydroxyl alkane
One or more of base, carboxylic acid group and carboxylic acid ester groups substituent is replaced;
R8For hydrogen atom or alkyl;
R9And R10It is each independently hydrogen atom or alkyl;
Or, R9And R10Heterocyclic radical is formed together with the nitrogen-atoms being connected, wherein containing 1~2 phase in described heterocyclic radical
The same or different hetero atoms for being selected from N, O and S, and described heterocyclic radical is optionally selected from alkyl, alkoxy, halogen, amino, carboxylic
One or more of acidic group and carboxylic acid ester groups substituent are replaced.
4. the compound according to logical formula (I) according to any one of claims 1 to 3, it is the change shown in logical formula (III)
Compound:
Or its dynamic isomer, mesomer, racemic modification, enantiomter, diastereoisomer or its form of mixtures, or
Its officinal salt,
Wherein:
G、R6~R7And R2As defined in claim 1.
5. the compound shown in logical formula (I) according to any one of Claims 1 to 4, wherein R2Selected from hydrogen atom, alkyl, ring
Alkyl and aryl, preferably hydrogen atom, methyl, ethyl, cyclopropyl or phenyl.
6. the compound according to logical formula (I) according to any one of claims 1 to 5, wherein the compound is selected from:
7. according to compound or its salt according to any one of claims 1 to 6, wherein described salt is logical formula (I) and trifluoro
The addition salts of acetic acid formation.
8. the compound shown in a kind of logical formula (IV):
Or its dynamic isomer, mesomer, racemic modification, enantiomter, diastereoisomer or its form of mixtures or
Its pharmaceutically useful salt,
Wherein:
W is amino protecting group;
G and R1~R2As defined in claim 1.
9. the compound shown in logical formula (IV) according to claim 8, it is selected from:
10. a kind of method for preparing the compound shown in logical formula (I) according to claim 1, this method includes:
Formula (I-5) compound is reacted with formula (I-6) compound, obtains logical formula (IV) compound;Obtained logical formula (IV)
Compound further sloughs protection group, obtains logical formula (I) compound;
Wherein:
W is amino protecting group;
G、R1And R2As defined in claim 1.
11. a kind of pharmaceutical composition, it contains the logical formula (I) institute according to any one of claim 1~7 of therapeutically effective amount
The compound shown, and one or more pharmaceutically acceptable carriers, diluent or excipient.
12. the compound or according to claim 11 shown in logical formula (I) according to any one of claim 1~7
Use of the pharmaceutical composition in the medicine of relevant disease of prevention and/or the activator mediation for the treatment of kappa opioid nonopioid receptors is prepared
On the way.
13. purposes according to claim 12, wherein the relevant disease of described kappa opioid nonopioid receptors activator mediation
Selected from pain, inflammation, itch, oedema, hyponatremia, hypopotassaemia, intestinal obstruction, cough and glaucoma, preferably pain.
14. the compound or pharmaceutical composition according to claim 11 according to any one of claim 1~7 are in system
Purposes in the standby medicine for preventing and/or treating pain and pain related disorders.
15. purposes according to claim 14, wherein described pain is selected from neuropathic pain, trunk pain, splanchnodynia, skin
Skin pain, arthritis ache, kidney stone pain, hysterotrismus, dysmenorrhoea, endometriosis, indigestion, surgical site infections pain
Bitterly, pain, ocular pain, otitis pain, explosive cancer pain and the disorderly related pain of GI after medical treatment.
16. the compound or according to claim 11 shown in logical formula (I) according to any one of claim 1~7
Pharmaceutical composition purposes in the medicine for preparing exciting kappa opioid nonopioid receptors.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2016100988566 | 2016-02-23 | ||
CN201610098856 | 2016-02-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107098871A true CN107098871A (en) | 2017-08-29 |
CN107098871B CN107098871B (en) | 2021-07-02 |
Family
ID=59674757
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710095021.XA Active CN107098871B (en) | 2016-02-23 | 2017-02-22 | Phenyl propionamide derivative, preparation method and medical application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107098871B (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018059331A1 (en) * | 2016-09-27 | 2018-04-05 | 四川科伦博泰生物医药股份有限公司 | Polyamide compound and use thereof |
WO2018103624A1 (en) * | 2016-12-06 | 2018-06-14 | 江苏恒瑞医药股份有限公司 | USE OF κ OPIOID RECEPTOR AGONIST IN PREPARATION OF DRUG FOR TREATING PRURITUS CAUSED BY FARNESOL X RECEPTOR AGONIST |
WO2018188641A1 (en) | 2017-04-14 | 2018-10-18 | 江苏恒瑞医药股份有限公司 | Pharmaceutical composition containing mor agonist and kor agonist, and uses thereof |
WO2020098563A1 (en) * | 2018-11-15 | 2020-05-22 | 四川科伦博泰生物医药股份有限公司 | Pharmaceutical composition comprising polypeptide compound, preparation method therefor and use thereof |
CN111233974A (en) * | 2019-11-12 | 2020-06-05 | 成都诺和晟泰生物科技有限公司 | Polypeptide compound, pharmaceutical composition, preparation method and application |
CN114615976A (en) * | 2019-08-07 | 2022-06-10 | 人福医药美国公司 | Kappa opioid receptor peptide amide agonists |
US11492374B2 (en) | 2020-06-25 | 2022-11-08 | Humanwell Pharmaceutical US | Peptides for treatment of medical disorders |
WO2023179659A1 (en) * | 2022-03-23 | 2023-09-28 | 江苏恩华药业股份有限公司 | Polyamide compounds, method for preparing same, and medical use thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101627049A (en) * | 2006-11-10 | 2010-01-13 | 卡拉治疗学股份有限公司 | Synthetic peptide amides |
US20100075910A1 (en) * | 2006-11-10 | 2010-03-25 | Cara Therapeutics, Inc. | Synthetic peptide amides and dimeric forms thereof |
-
2017
- 2017-02-22 CN CN201710095021.XA patent/CN107098871B/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101627049A (en) * | 2006-11-10 | 2010-01-13 | 卡拉治疗学股份有限公司 | Synthetic peptide amides |
US20100075910A1 (en) * | 2006-11-10 | 2010-03-25 | Cara Therapeutics, Inc. | Synthetic peptide amides and dimeric forms thereof |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109563133B (en) * | 2016-09-27 | 2020-09-11 | 四川科伦博泰生物医药股份有限公司 | Polyamide compound and use thereof |
CN109563133A (en) * | 2016-09-27 | 2019-04-02 | 四川科伦博泰生物医药股份有限公司 | Multiamide compound and application thereof |
US11084847B2 (en) | 2016-09-27 | 2021-08-10 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Polyamide compound and use thereof |
WO2018059331A1 (en) * | 2016-09-27 | 2018-04-05 | 四川科伦博泰生物医药股份有限公司 | Polyamide compound and use thereof |
WO2018103624A1 (en) * | 2016-12-06 | 2018-06-14 | 江苏恒瑞医药股份有限公司 | USE OF κ OPIOID RECEPTOR AGONIST IN PREPARATION OF DRUG FOR TREATING PRURITUS CAUSED BY FARNESOL X RECEPTOR AGONIST |
WO2018188641A1 (en) | 2017-04-14 | 2018-10-18 | 江苏恒瑞医药股份有限公司 | Pharmaceutical composition containing mor agonist and kor agonist, and uses thereof |
CN109982699A (en) * | 2017-04-14 | 2019-07-05 | 江苏恒瑞医药股份有限公司 | A kind of medical composition and its use of MOR agonist and KOR agonist |
CN112739709A (en) * | 2018-11-15 | 2021-04-30 | 四川科伦博泰生物医药股份有限公司 | Pharmaceutical composition containing polypeptide compound and preparation method and application thereof |
WO2020098563A1 (en) * | 2018-11-15 | 2020-05-22 | 四川科伦博泰生物医药股份有限公司 | Pharmaceutical composition comprising polypeptide compound, preparation method therefor and use thereof |
CN114615976A (en) * | 2019-08-07 | 2022-06-10 | 人福医药美国公司 | Kappa opioid receptor peptide amide agonists |
CN111233974B (en) * | 2019-11-12 | 2021-02-26 | 成都诺和晟泰生物科技有限公司 | Polypeptide compound, pharmaceutical composition, preparation method and application |
CN111233974A (en) * | 2019-11-12 | 2020-06-05 | 成都诺和晟泰生物科技有限公司 | Polypeptide compound, pharmaceutical composition, preparation method and application |
US11643436B2 (en) | 2019-11-12 | 2023-05-09 | Chengdu Sintanovo Biotechnology Co., Ltd. | Polypeptide compound, pharmaceutical composition, preparation method and application thereof |
US11492374B2 (en) | 2020-06-25 | 2022-11-08 | Humanwell Pharmaceutical US | Peptides for treatment of medical disorders |
WO2023179659A1 (en) * | 2022-03-23 | 2023-09-28 | 江苏恩华药业股份有限公司 | Polyamide compounds, method for preparing same, and medical use thereof |
Also Published As
Publication number | Publication date |
---|---|
CN107098871B (en) | 2021-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107098871A (en) | Phenylpropionyl amine derivant, its preparation method and its in application pharmaceutically | |
TWI781938B (en) | Phenyl acrylic amide derivatives, preparation process thereof and pharmaceutical use thereof | |
JP6927999B2 (en) | Degradation and use of CDK9 by conjugation of cyclin-dependent kinase 9 (CDK9) inhibitor with E3 ligase ligand | |
CN109983007A (en) | Amide derivatives inhibitor and its preparation method and application | |
CN105315285B (en) | 2,4 2 substitution 7H pyrrolo-es [2,3 d] pyrimidine derivatives, its preparation method and purposes pharmaceutically | |
CN109071552A (en) | The degradation and application method that cell cycle protein dependent kinase 4/6 (CDK4/6) passes through the conjugation of CDK4/6 inhibitor and E3 ligase ligand | |
WO2021023233A1 (en) | Egfr protein degradant and anti-tumor application thereof | |
WO2022268230A1 (en) | Compound as kif18a inhibitor | |
CN106883194A (en) | Oxadiazole analog derivative, its preparation method and its in application pharmaceutically | |
CN110156786A (en) | Pyrimido cycle compound and its preparation method and application | |
KR20170095919A (en) | Fused ring heteroaryl compounds and their use as trk inhibitors | |
CN107540594A (en) | The substituted formamide of pyrrolidines 2 | |
CN109310671A (en) | Bruton's tyrosine kinase inhibitor | |
CN107098876A (en) | Phenylpropionyl amine derivant, its preparation method and its in application pharmaceutically | |
CN107033097A (en) | Oxadiazole analog derivative, its preparation method and its in application pharmaceutically | |
CN110461842A (en) | Condensed five rings imdazole derivatives as TNF active regulator | |
IL268565A (en) | Pyrazole derivatives as bromodomain inhibitors | |
TW200306822A (en) | Imidazo[1, 2-a]pyridine derivative | |
CN107207476A (en) | Indoles and 7-azaindole derivatives and its for the purposes in neurodegenerative disorders | |
AU2004245198A1 (en) | Indole derivatives with apoptosis-inducing effect | |
TWI753550B (en) | Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease | |
WO2023138343A1 (en) | New type pyrazolopyrimidine compound and composition thereof, preparation method therefor and use thereof | |
WO2023198172A1 (en) | Oxadiazole compound, pharmaceutical composition comprising same, and use thereof | |
CN118619950A (en) | Tricyclic compounds, preparation and application thereof | |
CN116348109A (en) | Piperazine derivative, and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |